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 Three populations of activated macrophages were generated in vitro and 
characterized each. These include the classically (Ca-MΦ), alternatively (AA-MΦ), 
and type II activated (MΦ-II) macrophages. Here, a side-by-side comparison of the 
three cell types is presented, focusing primarily on differences between MΦ-II and 
AA-MΦ, because both have previously been classified as M2 macrophages, distinct 
from Ca-MΦ. I show that MΦ-II are similar to Ca-MΦ in that MΦ-II and Ca-MΦ, but 
not AA-MΦ, produce high levels of NO and have low arginase activity. MΦ-II and 
Ca-MΦ express relatively high levels of CD86, whereas AA-MΦ are virtually devoid 
of this co-stimulatory molecule. Ca-MΦ and MΦ-II are efficient antigen presenting 
cells (APCs), whereas AA-MΦ fail to stimulate efficient T-cell proliferation. The 
differences between Ca-MΦ and MΦ-II are more subtle. Ca-MΦ produce IL-12/23 
and give rise to Th1 cells when used as APCs. MΦ-II produce high levels of IL-10 
and low IL-12 and thus give rise to Th2 cells secreting IL-4 and IL-10.  I identify two 
   
new markers for the MΦ-II, sphingosine kinase and LIGHT. Thus, classically, type II, 
and alternatively activated macrophages represent three distinct populations of cells 
with different biological functions. 
 The expression of Heparin-Binding Epidermal Growth Factor-like Growth 
Factor (HB-EGF) by MΦ-II is then characterized. HB-EGF has previously been 
associated with a number of physiological and pathological conditions, including 
tumor growth and angiogenesis. MΦ-II exhibit increased HB-EGF mRNA levels and 
protein secretion relative to resting and Ca-MΦ. HB-EGF induction is dependent 
upon the activation of the MAPKs ERK1/2 and p38. The transcription factor, Sp1, 
was recruited to 3 sites within the first 2kb of the HB-EGF promoter following 
stimulation, and the site located at -83/-54 was required for HB-EGF promoter 
activity. These regions of the promoter became more accessible to endonuclease 
activity following activation, and this accessibility was contingent upon activation of 
ERK. We show that several conditions which enhanced macrophage IL-10 production 
also resulted in HB-EGF induction, suggesting that these two genes may be 
coordinately regulated.  These observations indicate that in addition to the secretion 
of the anti-inflammatory IL-10, another characteristic of MΦ-II is their production of 
angiogenic HB-EGF. 
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 The innate immune response is the first line of defense against potential 
pathogens. Unlike the adaptive immune response, defensive mechanisms mediated by 
cells of the innate immune response are at full potential before an encounter with an 
invading microbe. These responses are mediated primarily by neutrophils, dendritic cells, 
macrophages and natural killer (NK) cells. Oftentimes the initial innate immune response 
is sufficient to prevent infection and eliminate the invading microbe. If this is not the 
case, innate immunity works to initiate the adaptive immunity. Adaptive immune cells 
can in turn contribute to the initiation of the full repertoire of mechanisms of innate 
immunity. The cytokine interferon-γ (IFN-γ), for example, can be produced by both 
innate and adaptive immune cells and contribute to the full activation of macrophages. 
This in turn initiates the full repertoire of their microbicidal abilities. Futhermore, 
opsonization of invading microorganisms or their toxins by antibody, a product of B-
cells, can mediate their phagocytosis and destruction by cells of the innate immune 
system. Therefore, although innate and adaptive immunity are thought of as two separate 
“arms” of the immune system, there is a high degree of codependence by which one can 
not fully function without the presence of the other.    
 Cells of innate immunity express a variety of receptors which allow them to 
efficiently discriminate between self and non-self. These receptors recognize structurally 
conserved motifs of microbes which are essential and thus cannot readily be discarded by 
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microbes. These structurally conserved elements are known as PAMPs, or pathogen 
associated molecular patterns, and are recognized by pattern recognition receptors 
(PRRs). These receptors include the mannose receptors, scavenger receptors, receptors 
for opsonins, mannose-binding lectin, receptors for chemotactic factors, and the signaling 
pattern-recognition receptors (PRRs), which will be discussed in detail below. PAMPs 
share several common features including that they are usually produced by microbes, but 
not the host. Additionally, PAMPs are usually vital for the microbial pathogen’s survival 
or pathogenicity. Furthermore, these structures are usually shared by large classes of 
microbes and not specific pathogens. These include structural components of bacteria, 
such as lipopolysaccharide (LPS), or nucleic acids, such as the double stranded RNA 
(dsRNA) of some viruses. 
 The mannose receptor is a lectin found on macrophages that binds to terminal 
mannose and fucose residues found on microbial cell walls. Scavenger receptors bind 
anionic polymers and acetylated low-density lipoprotein
1
. Receptors for opsonins include 
the receptors for IgG (Fcγ-receptors), discussed in detail below, and the complement 
receptors. The complement receptors bind to activated or degraded portions of 
complement associated with microbes, notably fragments of the C3 protein
2
. Bacterial 
proteins initiate with N-formylmethionyl residues. Short peptides containing these 
residues serve as chemotactic factors to innate immune cells, especially NK cells. 
Binding to these receptors initiates a number of different effector functions, including 
phagocytosis, production of reactive nitrogen and reactive oxygen intermediates (RNI 
and ROI, discussed below) to kill phagocytosed microbes, release of cytokines, 
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chemotaxis, etc. The signaling PRRs, the Toll-like receptors (TLRs) and the cytoplasmic 
PRRs, are discussed in detail below.         
 
Signalling Pattern-Recognition Receptors 
 One important element of innate immunity is a limited number of germline-
encoded signaling pattern-recognition receptors (PRRs). There appear to be two main 
groups of these receptors, the toll-like receptors (TLRs) and the cytoplasmic PRRs.
 The first group of these receptors, the TLRs, is expressed by many cells of the 
immune system, including macrophages and dendritic cells, as well as non-immune cells 
such as epithelial cells. Thirteen potential TLRs are now recognized, although the 
functions of some are currently not understood. TLRs 1, 2, 4, 5, 6, 10, and 11 are 
expressed on the cell surface while TLRs 3, 7, 8, and 9 are found almost exclusively in 
intracellular compartments such as endosomes
3
. The TLRs recognize a variety of 









, etc. It is important to note, however, that 
although TLRs recognize specific PAMPs, there can be a great deal of diversity in the 
TLR ligands for a specific TLR. TLR4, for example, not only binds LPS, but structurally 
unrelated molecules such as fungal mannan, the fusion protein of respiratory syncytial 
virus, fibrinogen, etc.
3
 Mutations in toll like receptors render the host more susceptible to 
infection with the pathogen meant to be recognized. For example, TLR2 deficient mice 
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 The TLRs are very successful at detecting most potential pathogens at the cell 
surface or within endosomes, but they are ineffective at detecting pathogens that have 
invaded the cytosol. The NOD-LRR (nucleotide binding oligimerization domain-leucine 
rich repeat) proteins, which include the NOD and NALP proteins, and the CARD 
(caspase recruitment domain)-helicase  proteins recognize bacterial and viral 
components, respectively. For example, NOD1 and NOD2 recognize different portions of 
bacterial peptidoglycan
9,10
, whereas RIG-1 (retinoic-acid-inducible protein-1) and MDA-
5 (melanoma differentiation associated gene 5) have been recognized as detectors of 
cytoplasmic dsRNA (viral dsRNA)
11,12
. Recently, the factor DAI (DNA-dependent 
activator of IFN-regulatory factors), which belongs to neither the NOD-LRR nor the 
CARD-helicase protein families, has been recognized as the cytoplasmic detector of 
dsDNA
13
. A list of known PRRs and select list of their associated ligands is present in 
table 1.  
 It is important to note, however, that the TLRs also recognize some host-derived 
antigens in addition to microbial antigens. Most of these antigens are released a result of 
injury, cell death, or inflammation. This includes extracellular matrix (ECM) 
components, heat shock proteins (HSP), and host-derived nucleic acids
14
. 
 Although differing in the specific signaling pathways derived from ligand 
binding, the pattern-recognition receptors, in general, converge to activate similar factors 
downstream. This includes activation of the mitogen activated protein kinases (MAPK), 
nuclear factor-κ B (NF-κB), and the interferon regulatory factors (IRF), which results in 
the production of inflammatory cytokines and type I interferons (IFN-α/IFN-β). TLR4 
specifically activates two separate, yet intertwining pathways known as the MyD88-  






TLR1 Triacyl lipopeptides 
TLR2 Lipoproteins, Lipoteichoic Acid, Porins, Zymosan, 
Lipoarabinomannan, Phospholipomannan, tGP1-mutin, 
Hemaglutinin protein 
TLR3 dsRNA 
TLR4 Lipopolysaccharide, Mannan, 
Glycoinositolphospholipids, Viral Envelope Proteins, 
Heat Shock Proteins, Fibrinogens, Hyaluronic Acid, 
Heparin Sulfate, β-defensin 2, HMGB-1, Surficant 
Protein-A, gp96   
TLR5 Flagellin 
TLR6 Lipoproteins, Lipoteichoic Acid, Zymosan 
TLR7 ssRNA, Imidazoquinoline (synthetic 
compound), Loxoribine (synthetic 
compound), Bropirimine (synthetic compound) 
TLR8 ssRNA 
TLR9 CpG-DNA, Hemozoin 
TLR11 profilin-like protein 
NOD1 Cytoplasmic γ-D-glutamyl-meso-diaminopimelic acic 
(iE-DAP of peptidoglycan) 
NOD2 Cytoplasmic Muramyl dipeptide (MDP of 
peptidoglycan) 
MDA-5 Cytoplasmic dsRNA 
NAIP5 Cytoplasmic L. pneumophila (specific ligand unknown) 
NALP-3 Cytoplasmic Bacterial RNA, ATP, Uric Acid Crystals 
RIG-1 Cytoplasmic dsRNA 
DAI Cytoplasmic dsDNA 
 
Table 1: Pattern-Recognition Receptors (PRRs). PRRs and a selection of known 
endogenous and exogenous ligands.  
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dependant and MyD88-independent pathways (Figure 1). Activation of TLR4 leads to the 
activation of several adaptor proteins through the interaction with its intracellular TIR 
domain. Activation of TRAM leads to the activation of MyD88-independent pathways, 
while the activation of TIRAP and MyD88 leads to the activation of MyD88 dependant 
pathways. Activation of MyD88 subsequently leads to the activation of IRAK4, which 
dissociates and activates TRAF6. TRAF6 forms a complex to form an active 
polyubiquitin ligase, which through ubiquitination activates the MAP3K TAK1. TAK1 
forms a complex with TAB1/2/3 to activate the MAPK (mitogen activated protein kinase) 
pathways. TRAF6 can additionally lead to the activation of NF-κB through the activation 
of the IKK complex
15
.The MyD88-independent pathways, as mentioned above, are 
mediated through the adaptor TRAM, which in turn activates TRIF. TRIF activates RIP, 
which in turn activates the IKK complex, leading to the phosphorylation and subsequent 
degradation of IκB, the inhibitory subunit of NF-κB. NF-κB, free of its inhibitory 
subunit, is then able to translocate into the nucleus. TRIF also initiates the activation of 
the interferon regulatory factors, which is mediated by the TBK1/IKKi complex
15
.       
  
Fcγ-Receptors 
 One mechanism by which antibody is able to regulate immune responses is 
through the interaction with the Fc-receptors. Specifically, IgG antibodies interact with 
Fcγ-receptors (FcγRs) of which there are four classes, FcγRI, FcγRII, FcγRIII, and 
FcγRIV. In mice there are four known Fc-receptors, the high affinity FcγRI and the low 
affinity FcγRIIb, FcγRIII, and FcγRIV. All the FcγRs, except FcγRIIb, signal through an 
accessory immunoreceptor tyrosine based activating motif (ITAM)-containing γ-chain,  


































Figure 1: Toll-like receptor 4 (TLR4) mediated signaling pathways. 
The LPS/LPS binding protein (LBP) complex interacts with the LPS coreceptors CD14 
and MD2, leading to the activation of TLR4. Activation of TLR4 initiates a series of 
MyD88-dependant and MyD88-independent signaling pathways, ultimately leading to 
the activation of the interferon response factors (IRFs), nuclear factor-κ B (NF-κB), and 
the mitogen activated protein kinases (MAPK). This drives the production of 
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and thus are termed activating FcγRs. Signals arising from the cross-linking of the 
activating FcγRs are negatively regulated by the inhibitory FcγRIIb, whose cytoplasmic 
domain contains an immunoreceptor tyrosine based inhibitory motif (ITIM). Most innate 
immune effector cells express both activating and inhibitory FcγRs, whereas NK cells 
express only the activating FcγRIII and B cells express only the inhibitory FcγRIIb
16,17
. 
    Crosslinking of the activating FcγRs by immune complexes induces the 
phosphorylation of the ITAMs of the γ-chain by Src family kinases, which recruits and 
activates SYK. This directly activates a number of signal transduction molecules 
including Phosphoinositide 3-kinase (PI3K) and the guanine nucleotide exchange factor 
SOS (son of sevenless homolog). This results in the activation of a number of 
downstream signaling pathways, including the MAPKs and calcium dependant signaling 
pathways (Figure 2). Activation mediates a number of critical immune functions, 
including ADCC (antibody dependant cell-mediated cytotoxicity), phagocytosis, cytokine 
release, and the oxidative burst. Crosslinking of the inhibitory FcγRIIb induces the 
phosphorylation of the ITIM on its cytoplasmic tail, which recruits the phosphatase SHIP. 
The activation of SHIP interferes with signals generated by the activating FcγRs though 
hydrolysis of phosphoinositide intermediates generated by PI3K. Taken together, 
expression of the inhibitory FcγRs with the activating FcγRs controls excessive activation 
of the aforementioned functions
16,17
. 
 FcγRI, the high affinity Fcγ-receptor, binds monomeric IgG. In the human system, 
this receptor binds IgG1 and IgG3 tightly, while in the mouse, IgG2a and IgG2b are 
tightly bound. Unlike the other activating Fcγ-receptors, this receptor is constantly 
saturated with monomeric IgG and therefore the role of this receptor in binding immune  
































Figure 2: Activating Fc-γ Receptors. 
Crosslinking of the activating Fc-γ receptors by the presence of IgG-immune complexes 
results in phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) 
by a Src-family kinase (i.e. Lyn). Phosphorylated ITAMs recruit Syk through its SH2 
domain, which is then activated and in turn activates a number of downstream signaling 
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complexes is questioned. FcγRII and FcγRIII, also known as CD32 and CD16, 
respectively, are low affinity receptors which bind poorly, if at all, to monomeric IgG, but 
can bind to IgG immune complexes
17
. The recently discovered FcγRIV, whose 
expression is restricted to myeloid cells, binds exclusively to IgG2a and IgG2b
18
.   
 
Reactive Oxygen Intermediates and Reactive Nitrogen Intermediates 
 Activated macrophages have a number of mechanisms by which phagocytosed 
microbes are killed. Two important mechanisms are the generation of reactive oxygen 
intermediates (ROI) and reactive nitrogen intermediates (RNI). Generation of ROI is 
mediated by the multisubunit NADPH oxidase. Activation triggers translocation of 
cytosolic proteins to the membrane associated complex carrying cytochrome C. 
Activation is triggered by a number of stimuli, including microbial products, IFN-γ, IL-8, 
and FcγR crosslinking by IgG immune complexes. The reaction catalyzed by the NADPH 
oxidase generates superoxide (O2
-
). The primary ROI superoxide can be converted to a 
number of other reactive products, including H2O2 by SOD (superoxide dismutase), 




 Reactive nitrogen intermediates are generated by nitric oxide synthases (NOSs). 
NOSs convert L-arginine to L-citrulline and nitric oxide (NO). The intermediate product 
in this reaction, L-hydroxy-arginine, inhibits the opposing enzyme Arginase, discussed 
below
20
. The macrophage NOS, also known as inducible NOS (iNOS), is absent in 
resting cells. Its expression is regulated by a number of cytokines and microbial products. 
ROI and NO can combine to form peroxynitrite and other RNI. Nitric oxide reacts with 
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SH-groups of free cysteine or cysteine associated with proteins or peptides, resulting in 
S-nitrosothiols
19
. This can have an adverse affect on microbial proteins. For example, NO 
inactivates the Coxsackievirus cysteine protease 3C by S-nitrosylation of the cysteine 
residue in the active site, resulting in the disruption of the viral life cycle 
21




 Unlike the innate immune response, the adaptive immune response mediates 
recognition of specific antigens and not conserved motifs found on many potential 
pathogens. This is mediated by germline rearrangements of the antigen receptors for B 
and T lymphocytes, called the B-cell receptor and T-cell receptor (BCR and TCR), 
respectively. This allows for both antigen specificity as well as a great deal of diversity in 
the receptor repertoire. The power of adaptive immunity is immunological memory, 
which allows for changes in both the quality and quantity of the response upon 
reexposure to antigen. There are two types of adaptive immune responses, humoral and 
cell-mediated. These are mediated primarily by the B-cells and T-cells, respectively, and 
each eliminates different categories of organisms. Cell-mediated immunity is primarily 
generated against intracellular microbes, which survive and proliferate inside host cells. 
Cell mediated immunity leads to the destruction of the microbes or lysis of the infected 
cells. Humoral immunity is generated in response to extracellular microbes and their 
toxins. This is mediated by antibodies in the blood, the product of B lymphocytes. 
Antibodies specifically bind to antigens and neutralize their activity or target them for 
elimination by other effector mechanisms, such as complement and phagocytosis. The 
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focus below is antigen presentation to T-lymphocytes and sub-populations of T-
lymphocytes.   
 
T cells and Antigen Presentation to T-cells 
 Mature T cells are first divided into subsets based on their exclusive expression of 
either CD4 or CD8. The subsets are referred to as CD4
+
 helper or regulatory T cells and 
CD8
+
 cytotoxic T cells. CD4 or CD8 positivity defines which MHC complex can interact 
with the T cell. CD4
+
 T cells are restricted to interaction with the MHC class II, while 
CD8
+
 T cells are restricted to MHC class I. CD8
+
 T cells mature into cytotoxic T 
lymphocytes (CTLs), which function in the lysis of pathogen infected cells. CTLs release 
lytic granules containing perforin, granzymes, and granulysin, all of which contribute to 
the destruction of targeted cells. CD4
+
 T cells are further divided into distinct subsets 
based on their function and cytokine production, which is the focus below. These cells 
regulate the humoral and cell mediated immune responses. Naïve CD4
+
 T cells are 
activated by antigen presenting cells though the primary signal of the antigen specific T 
cell receptor (TCR) and CD4 interacting with peptide bearing MHC class II on the APC. 
This must be combined with a costimulatory signal of B7.1/B7.2 (CD80/CD86) 
interacting with CD28 on the surface of the T cell. Without this secondary signal the T 
cell goes into a state on non-responsiveness called anergy.  
 There are a several distinct populations of CD4
+
 T cells, which include both the 
“helper” T cell (Th) populations as well as the regulatory T cell populations (Tregs) 
(Figure 3). Currently there are three populations of Th cells recognized, and these are 
known as Th1, Th2, and Th17 cells. Th1 differentiation is the result of coordinate 
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signaling through the TCR and STAT1-associated cytokine receptors (i.e. IFN-γ), 
resulting in the upregulation of the master regulator of Th1 differentiation, the 
transcription factor T-bet
22
. T-bet drives expression of IFN-γ and the IL-12 receptor. 
Expression of the IL-12 receptor allows for IL-12 sensitivity, activating STAT4 which 
enhances IFN-γ expression and potentiates Th1 differentiation. Th2 differentiation is 
initiated by TCR signaling in combination with IL-4 receptor signaling through STAT6, 
resulting in the expression of the transcription factor GATA-3, the master regulator of 
Th2 differentiation
23
. GATA-3 enhances its own expression while driving epigenetic 
modifications to the Th2 gene cluster for the cytokines IL-4, IL-5, and IL-13
24,25
. 
Additionally, GATA-3 suppresses factors critical for Th1 differentiation, such as STAT4 
and the IL-12Rβ2 chain
26
. 
 Although the specific helper subsets are not exclusively present during an 
immune response, Th1 versus Th2 cells do generally play specific roles during an 
effective immune response. Th1 responses are generally thought to help in the clearance 
of intracellular pathogens. For example, their production of IFN-γ aids in the activation 
process of macrophages and strongly enhances their microbicidal effector functions. 
Conversely, Th2 can function in the control and clearance of extracellular pathogens. 
 Unchecked Th1 differentiation was until recently believed to be the cause of 
chronic inflammation, such as what is seen in the experimental models of autoimmunity, 
experimental autoimmune encephalitis or collagen induced arthritis. This was based on 
the fact that IL-12p40
-/-
 mice proved to be resistant to these pathologies
27
. Once it was 
discovered that the cytokine IL-23 uses the p40 subunit as well as the IL-23 specific 
subunit p19 that these studies needed to be reassessed
28
. Using IL-23p19 and IL-12p35 
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specific knockouts it was found that these pathologies were dependant on IL-23 and the 
IL-17 secreting T-cells, known as Th17 cells. The development of Th17 cells, however, 
is not dependant upon IL-23. IL-23 is able to drive IL-17 expression from memory 
populations, but not from naïve T-cells. Instead, the Th17 lineage is critically dependant 
upon TGF-β, proposed to be from a population of regulatory T-cells, as well as IL-6 from 
activated antigen presenting cells. Activation in the presence of these factors upregulates 
the IL-23 receptor, allowing for IL-23 responsiveness and thus potentiation of the Th17 
phenotype
29
.   
 The regulatory population of CD4
+
 cells also has several functionally distinct 
populations. There appears to be at least three different Treg populations, including the 
naturally occurring Tregs (nTregs) and two populations of adaptive or induced Tregs 
(aTregs). The nTregs develop intrathymically and are characterized by expression of the 
transcription factor Foxp3 (forkhead box P3) and contact dependant suppression of 
effecter T-cell development. They appear to suppress effector CD4
+
 T cell development 
before it begins and are important for controlling autoimmunity. In contrast, aTregs are 
distinguished from nTregs by their differentiation from naive CD4
+
 T cells in the 
periphery. They appear to develop in parallel to effector T cells to control effector T cell-
driven inflammation. There appears to be at least two populations of aTregs. The first, the 
Tr1 cells arise in response to IL-10 exposure and suppress through high expression of IL-
10. The second type, like the nTregs, expresses the transcription factor Foxp3. These are 
driven by exposure to TGF-β and are characterized by their expression of TGF-β
29
. An 
overview of the populations of CD4
+
 T-lymphocytes is present in Figure 3. 
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Figure 3: Populations of CD4+ T-lymphocytes. 
It was originally believed that CD4
+
 T-cells could either differentiate into IFN-γ secreting 
Th1 cells or IL-4 secreting Th2 cells, it is now widely believed that they can differentiate 
into IL-17 secreting Th17 cells as well as regulatory T-cell populations depending on 








 Cytokines are proteins secreted by the cells of the innate and adaptive immune 
response that mediate many of the effects of these cells. Most cytokines have both local 
and systemic effects, having autocrine, paracrine, and endocrine activity. Despite the fact 
that cytokines have diverse biological activities, they share several general properties in 
their influence on the immune system, in that they have pleiotropic, redundant, 
antagonistic, and synergistic properties. The pleiotropic property imparts their ability to 
have diverse biological functions. For example, tumor necrosis factor (TNF)-α’s 
autocrine activity helps to activate macrophages whereas its endocrine activity can 
influence cells of the hypothalamus to induce fever. The redundant property allows 
several cytokines to have the same or similar biological effects, for instance both 
interleukin (IL)-4 and IL-13 drive alternative activation of macrophages (see below). 
Cytokines can have both synergistic properties, in the case of TNF-α and IFN-γ which 
when combined can activate macrophages, and antagonistic properties, in the case of 
IFN-γ and IL-10 which activate and inhibit activation of macrophages, respectively. 
These properties allow the effects of cytokines to be amplified, but also tightly 
controlled.  
 During classical macrophage activation, as will be discussed, a number of 
important inflammatory cytokines are produced, including IL-1, IL-6, IL-12, IL-23, and 
TNF-α as well as low levels of the anti-inflammatory cytokine IL-10. Of these, IL-12, 
IL-23, and IL-10, are discussed in detail below.   
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IL-12 
 IL-12 is an important inflammatory cytokine produced primarily by dendritic cells 
and macrophages in response to stimulation with microbes or their products. It was 
originally identified in the supernatants of a human B-cell line infected with Epstein-Barr 
virus which had profound effects on natural killer (NK) and T-cells
30
. IL-12 is a 
heterodimeric cytokine consisting of a p40 subunit (IL-12α, 40kd) and p35 (IL-12β, 
35kd). IL-23 is an IL-12 family member which shares the p40 subunit. The heterodimer, 
known as IL-12p70, binds to the IL-12 receptor which consists of IL-12Rβ1 and IL-
12β2, expressed mainly by activated T-cells and NK cells. Once activated by the binding 
of IL-12p70, the IL-12R activates the JAKs TYK2 and JAK2, which are constitutively 
associated with IL-12Rβ1 and IL-12Rβ2, respectively. Activated Tyk2/Jak2 activate a 
number of the STATs, primarily STAT4, which drives most of the effects of IL-12. The 
p40 subunit is generally made in much higher concentrations than the p35 subunit or p19, 
the IL-23 equivalent. As a result, p40 is often secreted as a monomer or homodimer. In 
mice, but not humans, this homodimer has been shown to have an affinity for the IL-12 
receptor comparable to that of the heterodimer, despite the lack of biological activity
31
. 
Therefore, in some setting p40 homodimers can inhibit the activity of p70.  
 In general, activation of the TLR pathway is not sufficient to drive high levels of 
IL-12 production from macrophages. The presence of IFN-γ, coming primarily from Th1 
cells or NK cells, enhances the production of both subunits, thus increasing overall 
biologically active p70
32
. T-cells also enhance IL-12 production though interaction of 
surface associated CD40L with CD40 of macrophages or dendritic cells
33
. 
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 IL-12 production is negatively regulated by a number of conditions. This includes 
stimulation with the potent anti-inflammatory cytokine IL-10 and transforming growth 
factor (TGF)-β. Additionally, activation of a number of G-protein coupled receptors, such 
as EP2/EP4 (via treatment with prostaglandin E-2), α2-adrenergic, adenosine A2a, etc., 




 The primary function of IL-12 is to drive Th1 responses during T-cell activation. 
Activation of naïve CD4
+
 T-cells drives the upregulation of IL-12R. Stimulation with IL-
12 at this time drives the production of several cytokines, especially IFN-γ. This IFN-γ 
can then in turn help to further enhance the secretion of biologically active IL-12, thus 
driving a powerful positive feedback mechanism and commitment of CD4
+






 IL-23, as mentioned above, is a structurally related cytokine to IL-12. It shares the 
p40 subunit with IL-12, which combines with the p19 subunit to form the physiologically 
active IL-23. In addition to sharing a subunit, the receptor consists of IL-12βR1 and IL-
23 specific IL-23R. IL-23 has been shown to be essential for expansion of a population of 
CD4
+





 IFN-γ was originally identified in 1965 in the culture supernatants of 
phytohemagglutinin activated human leukocytes and was found to have antiviral 
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activity
35
. IFN-γ is produced primarily by NK cells, CD8
+
 T-cells, and CD4
+
 Th1 cells. 
Biologically active IFN-γ is a noncovalent homodimer which binds to the IFN-γ receptor 
(IFNGR), which consists of a high affinity ligand-binding α-chain (IFNGR1) and a 
signaling β-chain (IFNGR2). Binding to the receptor activates the Jak/Stat pathway, 
activating Jak1 and Jak2, which are constitutively associated with the α-chain and β-
chain, respectively, and Stat1
36
.     
 The main function of IFN-γ is to promote cell-mediated immunity against 
intracellular pathogens. IFN-γ aids in the activation process of macrophages and strongly 
enhances their microbicidal effector functions. One mechanism is by inducing the 
production of reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI) 
by macrophages. IFN-γ induces the production of RNI primarily by upregulating the 
inducible nitric oxide synthase (iNOS) as well upregulating the synthesis of the L-





, two components of the NADPH oxidase complex. 
IFN-γ also drives tryptophan depletion, primarily an antiparasitic mechanism, by 
generating N-formylkynurenine from free tryptophan via IDO. Another mechanism is the 
induction of the antiviral enzyme protein kinase R (PKR), which when activated by 
dsRNA inhibits the activity of eIF-2α, a factor involved in translation of cellular and viral 
RNAs. Another important function of IFN-γ is improvement of the antigen presenting 
function by enhancing antigen processing as well as presentation to T-cells by 
upregulation of MHC class I and class II
37
. Overall, the net effect of IFN-γ is to make 
macrophages much more efficient in their innate microbicidal functions and their 
contribution to the adaptive immune response. As a result, deficiencies in IFN-γ or IFN-γ 
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signaling render the host particularly susceptible to intracellular bacterial, parasitic, and 









 IL-10 is a potent anti-inflammatory cytokine produced by many cells of the 
immune system, including macrophages, helper T cells, regulatory T cells, mast cells, 
and eosinophils. It was originally known as “cytokine synthesis inhibitory factor” due to 
its ability to suppress Th1 cell function by Th2 cells
41
. Functional IL-10 forms a non-
covalent homodimer that binds to the ligand binding subunit of the IL-10 receptor (IL-
10Rα). IL-10Rα associates with IL-10Rβ, the signaling subunit. Lacking either subunit 
renders cells refractory to the effects of IL-10. Binding triggers activation of the 
Jak/STAT pathway, utilizing Jak1/Tyk2 and primarily Stat3. Stat1 and Stat5 (in non-
macrophage cells) have also been implicated
42
. 
 Although IL-10 was originally identified as a cytokine produced by Th2 helper T 
cells, it is known to be produced by a number of T cell subsets. IL-10 has been found to 
be produced by IFN-γ producing Th1 cells in response to Toxoplasma gondii 
43
 and 
infection with NIH/Sd strain Leishmania major
44
. It is believed that the production of IL-
10 in these systems is to moderate what could potentially be an excessive inflammatory 
response and thus limit damage to the host. IL-10 is also produced by a population of 
regulatory T-cells. This population of cells seems to arise in response to repeated 
administration of antigen in conditions promoting T-cell anergy. These Treg cells are 
able to block proliferation of naïve cells in an IL-10 dependant manner
45
. 
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 IL-10 essentially “deactivates” macrophages and makes them refractory to 
activating stimuli. IL-10 inhibits most cytokine and chemokine secretion by activated 
macrophages. These include the inflammatory cytokines IL-1, IL-6, IL-12, and TNF, as 
well as anti-inflammatory IL-10 itself. IL-10 also down-regulates Cox-2, the enzyme 
responsible for prostaglandin E(2) synthesis. Additionally, IL-10 up-regulates antagonists 
of inflammatory cytokine function, such as IL-1 receptor antagonist and soluble TNF 
receptor
42
. It is important to note, however, that IL-10 is typically made by macrophages 
late after activation and in relatively low quantities and therefore is thought to control 
excessive inflammation.  
 In addition to blocking the production of secreted factors, IL-10 affects surface 
associated proteins of macrophages. Importantly, IL-10 blocks the antigen-presenting cell 
(APC) function of macrophages by driving the downregulation of major 
histocompatibility complex class-II (MHC class II) and the costimulatory molecules B7.1 
and B7.2, which are both required for the activation of naïve T-cells. However, IL-10 
drives the upregulation of macrophage Fcγ receptors CD16 and CD64, the low and high 
affinity FcγRIII and FcγRI, respectively. This allows for enhanced uptake of opsonized 
particles or potential pathogens. This is contrast to the decreased ability to dispose of 





The Role of IL-10 in the maintenance of homeostasis and disease 
 The importance of IL-10 in the maintenance of homeostasis is best observed in 
the model of the IL-10 knockout (IL-10
-/-
) mouse. In a model of endotoxic shock, IL-10
-/-
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mice succumbed to lethal endotoxemia at a far lower concentration of LPS, which was 





spontaneously develop mucosal inflammation in response to enteric flora. Conventionally 
housed mice develop severe disease with lesions affecting both the upper and lower 
gastrointestinal (GI) tract, while mice housed in specific pathogen free conditions 
develop more mild disease restricted to the colon. Lesions within the GI tract contain 
large numbers of inflammatory cells, including macrophages, B-cells, and CD4
+
 T-cells 
with abnormally high levels of the inflammatory cytokines IL-1, IL-6, IL-12 and TNF. T-
cells within lesions were dominantly Th1 cells producing high levels of IFN-γ, which 




 There is clear evidence that manipulation of IL-10 cytokine levels has a profound 
effect of the outcome of infectious diseases. In many instances, in susceptible models of 
infection, production of IL-10 allows for persistence of infection. In models where IL-10 
has been manipulated though use of an IL-10 knockout or a neutralizing antibody to IL-
10, oftentimes there is enhanced disease resistance. Conversely, when IL-10 levels are 
increased by use of recombinant IL-10 or a transgenic pathogen, there is enhanced 
disease susceptibility
42
. Manipulation of IL-10 by these methods showing these effects 










, and the protozoa Leishmania major
55,56
.  
 In the case of leishmaniasis, however, it appears that the manipulation of IL-10 
levels is more complicated. In susceptible mouse models of cutaneous leishmaniasis, the 
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production of IL-10 plays a detrimental role by promoting disease progression. Infection 
of IL-10
-/-
 mice on a normally susceptible background results in relative resistance to 
disease progression
55
. IL-10 produced from macrophages due to the presence of 
opsonized parasites allows for dramatic enhancement of parasite intracellular 
survival
55,56
. However, in healing models of infection, the presence of IL-10 secreting 
regulatory T-cells is thought to sustain immunity to reinfection by allowing for antigen 
persistance. IL-10, in this case, controls complete eradication of parasites driven by 
effector T-cells. Infection of IL-10 knockout mice that are on normally resistant 
background results in sterile clearance of the parasite
57
. Complete clearance, however, 
results in loss of immunity to reinfection, indicating that the equilibrium established 
between effector and regulatory T cells allows for control of initial infection while 
promoting resistance to reinfection
57
. This observation, however, is considered 
controversial.    
 In general, IL-10 is important for establishing equilibrium between protective and 
detrimental inflammatory responses. IL-10 may control the absolute effectiveness of anti-
pathogen responses, but at the same time it is limiting potentially significant and 
irreparable damage to the host.   
 
Monocyte and Macrophage Heterogeneity and Macrophage Development 
Overview 
 Macrophages are specialized immune cells, which contribute primarily to innate 
immunity and serve as a bridge to adaptive immunity. Macrophages develop from 
circulating peripheral blood mononuclear cells (PBMCs) after migration into tissues 
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during homeostasis or in response to inflammatory stimuli. Monocytes develop in the 
bone marrow from a common myeloid progenitor, a precursor for a number of cell types 
including neutrophils, eosinophils, basophils, macrophages, dendritic cells (DCs), and 
mast cells. Specifically, during monocyte development common myeloid progenitors 
develop into granulocyte/macrophage colony forming units (CFUs), which sequentially 
develop from monocyte CFUs, to monoblasts, to pro-monocytes, and then finally 
circulate in the blood stream as monocytes. In response to infections or in order to 
replenish long-lived tissue-specific macrophages of the bone, alveoli, central nervous 
systems, connective tissue, gastrointestinal tract, liver, spleen, peritoneum, etc., 
monocytes migrate from the blood into the tissue. Macrophages can then perform a 
variety of functions, including clearance and killing of pathogens, clearance of apoptotic 
cells, contributing to tissue remodeling and wound healing, and maintenance of 
homeostasis (especially for long-lived resident macrophages). 
 
Monocyte Heterogeneity and Development of Macrophages 
 Monocytes are a relatively heterogeneous population of cells, the functions of 
which are only recently being realized. It now appears that monocytes develop along a 
continuum and at what point along the maturation process that monocytes are recruited 
out of the blood may define their function. These monocyte subpopulations are defined 
by the expression (or lack thereof) of a set of surface markers, which in mice are defined 
by CCR2 (the receptor for the chemokine MCP-1), Ly6C, CCR7, CCR8, and CX3CR1. 




 cells and are known as 
‘inflammatory monocytes’. This population of cells is generally recruited from the blood 
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into inflamed tissue, where most develop into macrophages and contribute to clearance of 
pathogens and healing after trauma
58
. These macrophages appear to be relatively plastic 
and will respond to specific signals in the microenvironment in which they find 
themselves (discussed below). The appearance of these cells in an inflammatory focus 
generally correlates with control of an infection. For example, enhanced recruitment of 
‘inflammatory monocytes’ through the expression of MCP-1 by transgenic Leishmania 
during an infection resulted in greater parasite killing as compared mice infected with 
wild-type Leishmania
59
. Most of these ‘inflammatory monocytes’ that are recruited 
during inflammation become macrophages, but it appears that a fraction of these cells are 
able to migrate into the tissue then into the lymph nodes as DCs
60
.  
 ‘Inflammatory monocytes’ that are not initially recruited further mature along the 
continuum and begin to lose expression of Ly6C (Ly6C Intermediate) while increasing 
their expression of the chemokine receptors CCR8 and CCR7. These cells appear to be 
more prone to developing into dendritic cells, and their recruitment into tissue then 
migration back into the lymph nodes appears to be dependant upon then expression of 
CCR7 and CCR8 and their associated chemokine ligands
58
. These monocytes appear to 
be an intermediate between inflammatory monocytes and a third population of monocytes 
called ‘resident monocytes’ which have lost their expression of CCR2 and Ly6C and 
gained the expression of CX3CR1. This population has been hypothesized to contribute to 
the regeneration of tissue-resident macrophage populations
58
. It appears that this 
hypothesis is probably an over-simplification of what actually occurs. Specialized 
dendritic cells of the skin called Langerhans cells are self-renewing throughout life in 
steady state conditions, meaning that under normal conditions they are not repopulated by 
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‘resident monocytes’
61
. However, if Langerhans cells are depleted by UV irradiation, 
they are replenished by precursors from the bone marrow. Conversely, tissue-specific 
macrophages of the liver called Kuppfer cell are directly replaced by bone marrow 
progenitors
62
. Therefore, this ‘resident monocyte’ population may be the precursor cell 
responsible for replenishing these cells. It appears that this ‘resident monocyte’ 
population may contribute to the generation of certain tissue resident macrophages and 
DCs, but most likely not all of these cells.   
 
Heterogeneity of Activated Macrophages 
 Macrophages express a variety of receptors which allow them to respond to the 
microenvironment into which they are recruited. This includes responding to a variety of 
cytokines, chemokines, products derived from pathogens, etc. The combination of these 
stimuli drives the development of specific subpopulations of macrophages, including the 
classically activated macrophage (Ca-MΦ), the alternatively activated macrophage (AA-
MΦ), and the type II activated macrophage (MΦ-II). These phenotypes are highly 
reproducible in vitro and appear to reflect populations that appear in vivo (Figure 4). 
 
The Classically Activated Macrophage 
 Classically activated macrophages (Ca-MΦ) have been thoroughly characterized. 
They were initially characterized in 1964, where it was shown that infection of mice with 
Listeria monocytogenes, Brucella abortus, or Mycobacterium tuberculosis increased the 
bactericidal activity of macrophages
63
. As the name implies, they were once considered 
to be the only type of activated macrophage. These cells arise by exposure to two signals.  































Figure 4: Activated macrophage populations. 
Classically activated macrophages (Ca-MΦ) or M1 cells arise in response to IFN-γ as 
well as an activating stimulus, such as a Toll-like receptor ligand. Ca-MΦ cells produce a 
battery of inflammatory cytokines, as well nitrogen and oxygen radicals.  These 
macrophages produce low levels of the anti-inflammatory cytokine IL-10. Alternatively 
activated macrophages (AA-MΦ) arise in response to the Th2 associated cytokines IL-4 
and IL-13. These cells have been associated with a number of markers including FIZZ1, 
YM1, and the arginine consuming enzyme arginase-1. Additionally, the cells have been 
reported to express elevated levels of IL-10. The Type II activated macrophage arises in 
response to classical activating stimuli in the presence of Fcγ-Receptor signaling through 
the presence of IgG-immune complexes (i.e. an opsonized erythrocyte). This results in 
the suppression of IL-12 production and high levels of anti-inflammatory IL-10. The 
aims of this work are to characterize the MΦ-II in the context of the Ca-MΦ and the AA-




















Classically Activated Macrophage (M1)
Alternatively Activated Macrophage (M2a)
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The first is IFN-γ, which is necessary for priming but not sufficient for activation
64
. This 
first signal must be combined with an activating stimulus. This can be TNF-α or an 
inducer of TNF-α such as a toll like receptor (TLR) ligand. Once activated, these 
macrophages up-regulate the TNF receptor, which enhances the autocrine activity of 
TNF-α. CD40 also aids in activation by binding CD40L on IFN-γ secreting Th1 
cells
65
.Once activated, these macrophages serve a variety of functions. They up-regulate 
MHC class II and costimulatory B7, which enhances their ability to present antigens. 
They secrete a full battery of inflammatory cytokines including IL-12, IL-1, IL-6 and 
TNF-α, as well as modest amounts of anti-inflammatory IL-10. These cells are very 
effective in killing intracellular pathogens. Killing can be mediated by the production of  
reactive oxygen intermediates (ROI) and the activation of iNOS (inducible NO synthase), 
as well as by restriction of nutrients such as iron and tryptophan
65
.  





, and inflammatory bowel disease
68
, are associated 
with uncontrolled macrophage activation. This can also be applied to uncontrolled 
activation during chronic infections, such as mycobacterial infections. Some microbes 
can resist the microbicidal effects of activated macrophages, resulting in chronic 
infection. What often results is a granuloma, consisting of a central area of activated and 
often fused multi-nucleated macrophages surrounded by activated lymphocytes
65
. These 
collections of activated macrophages can induce tissue pathology, DNA damage, and 
occasionally give rise to cancer.    
 
The Alternatively Activated Macrophage 
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 The alternatively activated macrophage (AA-MΦ) was originally characterized in 
conditions that allowed for overexpression of the macrophage mannose receptor 
(MMR)
69
. The macrophage mannose receptor is important in the binding and 
phagocytosis of microorganisms with surface mannose residues. The MMR is expressed 
on tissue macrophages, but its expression decreases in response to IFN-γ activation. 
However, it was found that the Th2 associated cytokine IL-4 could enhance both MMR 
surface expression 10-fold and activity 15-fold
69
. It was later shown that both IL-4 and 
another type 2 cytokine, IL-13, were similar in their ability to induce the alternative 
activation phenotype
70
. The more recently described cytokine IL-21 also seems to play an 
indirect role by increasing responsiveness to IL-4 and IL-13
71
. AA-MΦ have been 




















 Perhaps the most important element of the AA-MΦ phenotype is differential L-
arginine metabolism relative to the classically activated macrophages. This was originally 
observed in the regulation of fibrotic liver pathology in response to type 1 versus type 2 
cytokines in mice infected with Schistosoma mansoni
20
. It had previously been shown 
that skewing the immune response towards Th1 could alleviate the pathogenic response 
due to the activation of iNOS, as mice deficient in this gene failed to control infection 
with S. mansoni. The induction of Arg-1 (Arginase-1) by macrophages was found to be 
type-2 cytokine dependant. Arg-1 hydrolyses L-arginine to urea and ornithine (Figure 5). 
Ornithine is required in the synthesis of proline and polyamines, which are required for  











Figure 5: L-arginine metabolism is differentially controlled by Th1 versus Th2 
associated cytokines by macrophages. 
NOS-2 (iNOS) is induced by the presence of Th1 cytokines, resulting in the production 
of nitric oxide (NO) and citrulline. Arginase is induced by Th2 cytokines, resulting in the 
production of urea and L-ornithine. L-ornithine is further metabolized by ornithine 
aminotransferase (OAT) or ornithine decarboxylase (ODC) to produce proline or 
polyamines, respectively. Figure reproduced with permission from the Journal of 
Immunology. Copyright 2001The American Association of Immunologists, Inc.
20
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cell proliferation and collagen production. As both iNOS and Arg-1 use arginine as a 
common substrate, cytokine mediated activation of one enzyme corresponds with the 
suppression of the other. The shift in a Th1 towards a Th2 reseponse correlating with a 
shift in arginine metabolism from iNOS activity towards Arg-1 is associated with the 
magnitude of pathology in this model
20
.  
 Subsequently many markers have been shown to be reliably associated 
withalternatively activated macrophages. In the murine disease model of Trypanosoma 
brucei brucei infection, early infection is characterized by the development of Ca-MΦ, 
whereas the chronic stages are characterized by AA-MΦ. It was shown that both FIZZ1 
(found in the inflammatory zone 1) and Ym1 are strongly induced in the late stages of 
infection. FIZZ1 is a secreted protein that has been associated with allergic and 
pulmonary inflammation. Ym1 is a secretory lectin that has been associated with lung 
inflammation due to its ability to form crystals in alveolar spaces, but also has been 
shown to have anti-inflammatory properties due to its ability to bind to local ECM and 
compete with leukocytes for binding sites. FIZZ1 and Ym1 were both shown to be 
strongly induced in the in vivo disease model and in vitro with IL-4 treatment. This was 
antagonized by the presence of IFN-γ. Insulin-like growth factor-I (IGF-I), a protein 
implicated in interstitial lung disease and pulmonary fibrosis, has also been associated 
with macrophages exposed to Th2 cytokines. IGF-I promotes the proliferation and 
survival of fibroblasts and stimulates collagen synthesis by them. AMAC1 (alternative 
macrophage activation-associated chemokine), IL-1 decoy receptor (an anti-inflammatory 
inhibitor of the effects of IL-1), TGF-β, and MMP-1 (matrix-metalloproteinase-1) have 
also been associated with AA-MΦ
80
.  It is unclear, however, if the presence of these 
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markers is as a direct result of Th2 cytokines, as they are associated with complex 
diseases. 
The kinetics of the induction of AA-MΦ seem to depend on the specific infection 
model being studied. Infection with the helminth H. polygurus only results in the 
accumulation of AA-MΦ during a memory response
73
. In contrast, during the N. 
brasiliensis infection model in SCID, mice which lack T-cells, AA-MΦ appear soon after 
infection, indicating that Th2 cytokines produced by innate immune cells are sufficient. 
Of note, however, is that AA-MΦ rapidly disappear in SCID mice while they are retained 




Although it appears that the generation of AA-MΦ plays a detrimental role in the 
immune system, especially in the model Schistosoma mansoni, this is certainly an 
oversimplification. The generation of AA-MΦ may control excessive inflammatory 
responses. Alternatively activated macrophages have been shown to suppress T-cell 
activation  in vivo and in vitro, possibly through TGF-β or interactions with programmed 
death-1 (PD-1) on T-cells with programmed death ligand-1 or -2 (PDL-1 and PDL-2)
81,82
 
on macrophages. During the murine model of inflammatory renal disease, infusion of ex 
vivo generated AA-MΦ ameliorates disease while Ca-MΦ exacerbate disease
83
. 
Additionally, it has been shown that microglial cells have an alternatively-activated 
phenotype (Ym-1 positive), and in the murine model of multiple sclerosis, IL-4 is critical 
for controlling the phenotype of infiltrating macrophages
84
. Additionally, the phenotype 
of adipose tissue macrophages is critical for protection against insulin resistance. Lean 
mice have macrophages with an alternatively activated phenotype, which are decreased in 
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response to diet induced obesity. However, this is not the case in mice predisposed to 
obesity and insulin resistance, which retain their AA-MΦ pehonotype. AA-MΦ in this 
model protect from TNF-α induced insulin resistance
85
. Another potential function of 
these cells is their contribution to wound healing. IL-4 activation of macrophages induces 
extracellular matrix (ECM) proteins fibronectin, tenascin-C, and βIG-H3 and ECM 
modifying enzymes matrix crosslinking-enzyme tissue transglutamase (tTG), matrix-
metalloproteinase (MMP)-1, and MMP-12
86
. 
In addition to the liver fibrosis associated with a Th2 dominant response to 
Schistosomiasis, AA-MΦ can play a detrimental role in other pathological conditions. In 
the murine model of Cryptococcus neoformans, a fungal disease typically associated with 
AIDS patients, the expression of IL-13 is responsible for disease susceptibility and drives 
the production of AA-MΦ
87
. In co-infection models, such as T. crassiceps with 
Leishmania or H. polygyrus with Citrobacter rodentium, generally effective 
inflammatory responses are overridden by helminth infection
88
.     
 
The Type II Activated Macrophage 
 The Type II activated macrophage (MΦ-II) was originally characterized in this 
lab while investigating scenarios that led to the abrogation of IL-12 transcription. 
Macrophages were stimulated with IFN-γ and LPS, conditions that normally promoted 
the production of IL-12 and classical activation, along with the presence of IgG 
opsonized-erythrocytes (E-IgG). These E-IgG ligated the Fcγ receptors, resulting in the 
production of large amounts of IL-10, coincident with the inhibition of IL-12 
production
89
. However, this was not the only scenario under which this cytokine skewing 
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could be reproduced. A variety of activating signals when combined with Fcγ receptor 
ligation with immune complexes, including the TLR4 ligand LPS and TLR2 ligand 
lipoteichoic acid (LTA), as well as mimicking T-cell CD40 ligand with an antibody 
against CD40 and with the endogenous TLR ligand low molecular weight hyaluronic acid 
(LMW-HA) all showed similar alterations in cytokine production. Importantly, cytokine 
modulation in response to immunce complexes was specifically limited to IL-10, IL-




 This phenomenon of enhanced IL-10 production was shown to have in vivo 
significance by reversing LPS associated toxicity. Mice were passively immunized with 
anti-LPS IgG and later injected with LPS. It was found that in mice given IgG against 
LPS had modest levels of IL-12 and high levels of IL-10 in the serum. Additionally, mice 
that were given macrophages activated in vitro with LPS in the presence of E-IgG then 
challenged with a lethal dose of LPS, survived. However, mice that were given 
macrophages stimulated with LPS or macrophages from IL-10 deficient mice stimulated 
with both LPS and E-IgG quickly succumbed to the effects of endotoxic shock
90
. 
 The name type II activated macrophage (MΦ-II) was later coined based on the 
ability of these macrophages to bias T-cells towards a Th2 phenotype. MΦ-II could bias 
T-cells differently than classically activated macrophages (Ca-MΦ). DO11.10 T-cells 
(transgenic OVA-specific) were activated with macrophages stimulated with either LPS 
plus ovalbumin (OVA) or macrophages stimulated with LPS and OVA in immune 
complexes (IgG-OVA). It was found that upon stimulation, T cells exposed to MΦ-II 
produced relatively low levels of IFN-γ and high levels of IL-4, whereas those stimulated 
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with Ca-MΦ produced low levels of IL-4 and high levels of IFN-γ. It was shown with IL-
10 and IL-12 deficient mice that the ability of Ca-MΦ and MΦ-II to bias T-cells towards 
Th1 and Th2, respectively, was contingent upon the reciprocal modulation of these two 
cytokines. Furthermore, this biasing was irreversible, as cytokine production remained 




  Type II activated macrophages have also been shown to influence the antibody 
response in mice. In these studies, DO11.10 mice were injected with a combination of 
OVA and in vitro activated macrophages (Ca-MΦ or MΦ-II). Mice receiving Ca-MΦ 
generated significant titers
 
of OVA-specific antibody, comprised of both IgG1 and IgG2a. 
Mice receiving MΦ-II generated antibodies of the same isotypes. Injection of MΦ-II, 
however, did result in the production of higher total antibody
 
levels, and this increase was 




.   
 It appears that in certain infections, MΦ-II could contribute to persistence due to 
the formation of immune complexes. Increases in pathogen numbers can overlap with 
high antibody titers, thus creating a scenario where immune complexes could easily form. 
The production of IL-10 in this case could potentially create a more favorable 
environment for intracellular pathogens and exacerbate disease. In the susceptible model 
of murine cutaneous leishmaniasis as well as human visceral leishmaniasis this seems to 
be the case. IgG-opsonized parasites drive the production of IL-10 from macrophages  




Deactivated Macrophage Phenotypes 
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 In addition to classically activated, type II activated, and alternatively activated 
macrophages, deactivated macrophages also seem to be a relevant population of 
macrophages. These are generated by a number of stimuli, including exposure to the 
cytokines IL-10 and TGF-β, treatment with glucocorticosteroids, or ligation of the 
inhibitory receptors SIRPα or CD200R by CD47 and CD200, respectively (generally by 
apoptotic cells). These cells downregulate MHC class II and produce higher levels of 
anti-inflammatory IL-10 and TGF-β
80
.   
 
Molecular Regulation of IL-10 in Macrophages 
mRNA Stability and Transcription Factors 
 There is general agreement that the most important aspect of the regulation of il-
10 gene expression occurs at the level of transcription.  However, similar to many other 
cytokines, IL-10 mRNA contains several potential mRNA-destabilizing sequences (AU-
rich elements) in the 3’-UTR of mouse and human IL-10 mRNA that make this mRNA 
relatively short-lived. Many cell types appear to express low levels of IL-10 mRNA, yet 
do not make detectable levels of IL-10 protein. Powell MJ, et al. systematically addressed 
the 3’-UTR of IL-10 mRNA and postulated that some cell types might constitutively 
transcribe low levels of IL-10 mRNA, but due to mRNA-destabilizing signals insufficient 
message persisted to allow detectable protein production. Therefore, it is certainly 
plausible that the increased IL-10 production associated with the activation of cells may 
not only be due to an induction of IL-10 transcription, but it may also involve some 
measure of increased mRNA stability
93
. 
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 A number of different transcription factors have been associated with the 





, CREB (cAMP-response element-binding 
protein)
96





, IRF-1 (interferon regulatory factor-1)
100
, and 
NF-κB (nuclear factor-κ B)
101
. The roles of Sp1, STAT3, and NF-κB will be discussed in 
detail.  
  The Sp1 binding site located at -89/-78 is a central mediator for murine IL-10 
production. LPS induced IL-10 promoter activity was shown to be dependant upon this 
element, despite the fact that activation of murine macrophages was not required for Sp1 
binding to labeled DNA oligonucleotides
94
. When it was originally described, Sp1 was 
shown to be phosphorylated by a DNA-dependent protein kinase, Sp1 kinase, to activate 
transcription
102
. However, work with the human IL-10 promoter indicates that Sp1 
phosphorylation depends on p38 MAPK. Stimulation of human macrophages in the 
presence of p38 inhibitors results in a dramatic curtailment of IL-10 production, but it is 
not clear whether this inhibition directly affects Sp1 phosphorylation or not
103
. 
 STAT3 binds to the human IL-10 promoter at -120 and mediates the upregulation 
of IL-10 production in multiple myeloma cell lines
97
. IL-10 itself can induce IL-10 
production in an autocrine fashion in human monocyte-derived macrophages via the 
activation of STAT3
104
. In murine cells it was demonstrated by ChIP (Chromatin 
Immunoprecipitation) that STAT3 potentially binds two sites (-629/-621 or -479/-471) of 
the IL-10 promoter following LPS stimulation
105,106
. This analysis, however, did not 
distinguish between binding to either site. STAT3 does not appear to be required for IL-
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10 transcription. Macrophages and neutrophils from conditional knockout mice actually 
exhibit higher IL-10 expression both in the serum and peritoneal fluid after endotoxin 
stimulation. Additionally, thioglycolate-elicited peritoneal macrophages from these mice 
had higher IL-10 production upon LPS stimulation
107
. Thus, while STAT3 clearly binds 
to the IL-10 promoter and participates in IL-10 transcription, this transcription factor 
does not appear to be required for IL-10 gene expression.   
 It was previously believed that NF-κB does not participate in any significant way 
in the regulation of IL-10 gene expression. The IL-10 promoter lacks the typical 
consensus NF-κB cis-elements. However, Mori and Prager reported that high IL-10 
expression correlated with high NF-κBp50 expression in a T cell line, suggesting that 
some NF-κB members may be involved in IL-10 transcription
108
. Cao et al. employed an 
overexpression approach to examine the role of individual NF-κB family members in IL-
10 gene expression. Overexpression of four of the five NF-κB family members, including 
p65, c-Rel, RelB, and p52 had no effect on IL-10 transcription. However, the 
overexpression of NF-κB1 (p50) caused a dramatic increase in IL-10 promoter-driven 
luciferase activity, whereas several different heterodimers actually inhibited activity. The 
conclusion was that p50 homodimers can promote IL-10 synthesis. Most importantly, 
p50 knockout mice are more susceptible to lethal endotoxemia as macrophages from 
these mice exhibit skewed cytokine responses to lipopolysaccharide, characterized by 




Epigenic Modifications and Regulation of IL-10 by the MΦ-II 
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 An important element of the regulation of IL-10 is epigenic modifications of the 
IL-10 promoter. This is evident in both macrophages and T-cells, albeit by different 
mechanisms. It has previously been shown that in T cells GATA3 induces remodeling of 
the chromatin structure at the IL-4 locus by binding to sites localized upstream of the IL-
4 gene and in the IL-4/IL-13 intergenic region. GATA3, however, only weakly 
transactivates the IL-4 promoter. On the same note, forced expression of GATA-3 in 
naïve T-cells resulted in enhanced expression of IL-10 driven by changes in the 
chromatin structure at the IL-10 locus. GATA3, in this case, does not transactivate the 
IL-10 promoter. Rather the role appears to be primarily in driving remodeling of the IL-
10 locus to be more transcriptionally competent
109
. A series of chromatin modifications at 
the IL-10 locus in differentiated Th1 and Th2 cells modulates repression and function of 
the IL-10 promoter, respectively. It is noteworthy that these chromatin modifications are 
long-term and heritable in daughter cells
110
.  
 Similar to T cells, macrophage IL-10 gene transcription is regulated both by 
modifying chromatin and by activation of necessary transcription factors. However, this 
mechanism appears to be quite distinct from that which occurs in T cells. In 
macrophages, transcription factor binding to the IL-10 promoter appears to be preceded 
by the transient phosphorylation of chromatin associated with the IL-10 promoter. The 
phosphorylation of histones associated with the IL-10 promoter is dependent on the 
activation of the mitogen-activated protein kinase (MAPK), ERK. The resultant histone 
phosphorylation makes the DNA accessible to transcription factors, allowing them to 
bind to the il-10 promoter
105,106
.  
 Thus, optimal IL-10 production by the type II activated macrophage is the result   




































Figure 6: Model for the regulation of IL-10 by Type II activated macrophages. 
Stimulation of macrophages with LPS alone activates the necessary transcription factors 
for IL-10, yet the “closed” confirmation of the IL-10 locus results in relatively inefficient 
transcription factor binding and thus inefficient transcription. However, stimulation with 
LPS in the presence of immune complex leads to rapid and prolonged ERK activation, 
leading to the activation of an undetermined ERK-dependant kinase. This ERK-
dependant kinase phosphorylates histone H3 (at S10), which results in a looser chromatin 
conformation and allows for efficient transcription factor binding and thus high IL-10 






















 41  
of a confluence of two cellular signaling pathways.  The first pathway activates the 
transcription factors that drive cytokine gene expression. This is usually initiated by the 
ligation of any of the Toll-like Receptors (TLRs). This first pathway is common to the 
inflammatory cytokines as well as IL-10, and TLR activation is the prototypical way that 
inflammatory cytokine genes are induced. The ligation of TLRs, however, is generallynot 
sufficient to induce high levels of IL-10 in macrophages because the necessary 
transcription factors do not gain access to the IL-10 promoter
105
.  
 There is, however, a second level of regulation that appears to be fairly unique to 
IL-10. This second signal required is the rapid and prolonged activation of ERK. This 
pathway is not activated by the typical Ras/Raf pathway that is associated with growth 
factor receptor signaling, but through activation of the protein tyrosine kinase Syk. This 
is achieved efficiently though the cross-linking of Fcγ receptors by immune complexes. 
The result of ERK activation is the phosphorylation of histone H3 associated with the IL-
10 promoter. This results in a more accessibility promoter, allowing for efficient 
transcription factor and thus a high level gene expression
105,106
. So, without the 
activationof ERK, these modifications do not occur and associated transcription factors 
are not efficiently able to gain access (Figure 6). 
 The kinetics of the chromatin modifications occurring to the promoter of IL-10 
appear to be quite unique. ERK activation results in the rapid phosphorylation of 
histones.  Phosphorylation peaks within 30 minutes of activation, with transcription 
factor binding following closely thereafter. Second, the phosphorylation is remarkably 
transient. By one hour post-stimulation there is no longer detectible phosphorylation of 
histones associated with the IL-10 promoter, and transcription rapidly subsides. The 
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kinetics of chromatin modifications of the IL-10 gene in macrophages are quite distinct 
from the well-described epigenetic modifications associated with the stable "marking" of 
genes for expression, i.e. IL-10 expression in Th2 T-cells. These studies concluded that 
macrophages undergo ERK-dependant transient modifications to the chromatin 
associated with the IL-10 promoter that temporarily make the promoter accessible to 
transcription factors. Additionally, the activation of the MAPK p38 is required for proper 




MAPK Mediated Chromatin Modifications 
Overview  
 The induction of IL-10 induction seems to follow the module of an immediate 
early (IE) gene, in that its induction is directly connected to signaling systems
111
. The IE 
module of gene regulation takes advantage of chromatin structure. Post-translational 
modification of histones, such as phosphorylation or acetylation, may alter DNA-histone 
contacts. Additionally, they may act as binding platforms for other proteins. For instance, 
bromodomains are proposed to interact with acetyl-lysine and chromodomains are 
proposed to interact with methyl-lysine of histones
111
. 
 IE genes can be regulated by several different signaling pathways, including the 
JAK/STAT, NF-κB, and MAPK pathways. However, the MAPK pathways, in particular 
p38 and ERK1/2, are associated with histone H3 modifications. The MAPK cascades can 
elicit a rapid and transient phosphorylation of H3 at serine 10 and/or 28 and the protein 
HMG-14 (High Mobility Group protein 14). This is known as the nucleosomal response. 
There are three candidate MAP kinase activated protein kinases (MKs) known to date 
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that may play are role in the nucleosomal response, all of which have been implicated in 
some system. These are MSK1 (mitogen and stress activated protein kinase), MSK2, and 
RSK2 (ribosomal S6 kinase). These three proteins belong to the larger MK family which 
is comprised of 11 members to date. They can be activated by p38 (MK2, MK3, and 
MK5), by ERK1/2 (RSK1-4 and MNK5), or by both p38 and ERK1/2 (MSK1, MSK2, 
and MNK1). Those involved in the nucleosomal response, the RSKs (p90 ribosomal S6 
kinases) and MSKs (mitogen and stress activated protein kinases), have two kinase 
domains. The N-terminal kinase domain (NTKD) seems to be important for substrate 
phosphorylation and autophosphorylation of several residues important for activation. 




The RSKs contain a D-domain near the C-terminus necessary for ERK1/2 
docking. Docking is a rather transient event as a serine residue near the D domain is 
rapidly phosphorylated which drives dissociation. These proteins are normally associated 
with the cytoplasm of quiescent cells, but upon stimulation a significant portion 
translocates to the nucleus. The MSKs are structurally very similar to the RSKs. They 
also contain a D-domain near the C-terminus necessary for the docking to ERK1/2 and 
p38. However, unlike the RSKs, the MSKs are predominantly nuclear in localization of 




Ribosomal S6 Kinase-2 (RSK2) and the Mitogen and Stress Activated Protein Kinases 
(MSK)1 and 2 
 44  
 Sassone-Corsi et al. initially investigated the ability of fibroblasts derived from 
patients with Coffin-Lowry syndrome (CLS), an X-linked mental retardation disorder 
caused by mutation of RSK2, to phosphorylate histone H3 in response to epidermal 
growth factor. Wild-type serum starved fibroblasts underwent rapid phosphorylation of 
histone H3 in response to epidermal growth factor. CLS derived RSK2 deficient 
fibroblasts, however, were unable to undergo phosphorylation of histone H3 in response 
to EGF. In addition, transfection of RSK2 expression vector restored the ability to 
phosphorylate H3 in response to EGF
113
.  
 Others have shown that MSK1 and/or MSK2 are more likely to be candidates for 
the H3 kinase involved in the nucleosomal response. Thomson et al. showed that the 
phosphorylation of H3 and HMG-14 in response to TPA (ERK dependant) or anisomycin 
(p38 dependant) could be inhibited by the protein kinase inhibitor H89. They 
demonstrated that that of these candidate H3 kinases, only the activity MSK1 was 
inhibited by H89. Additionally, MSK1 was found to have higher H3 and HMG-14 kinase 
activity relative to either RSK1 or RSK2
114
.  
 Soloaga et al. reported that MSK1 or MSK2 are the major kinases involved in the 
nucleosomal response to mitogenic or stress stimuli. Mouse fibroblasts from MSK double 
knockout cells were unable to phosphorylate histone H3 or HMG-14, and this activity 
could be restored with transfection with a construct encoding MSK2. Treatment of wild-
type fibroblasts with anisomycin resulted in transient induction of c-jun and c-fos. 
MSK1/2 knockouts, however, had significant reduction of c-fos induction and delayed 
induction of c-jun. Importantly, this group demonstrated that H3 phosphorylation was not 
affected in CLS derived cells despite the RSK2 deficiency. This group concluded that the 
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 Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) 
 The focus of chapter 4 is the regulation of heparin-binding epidermal growth 
factor-like growth factor (HB-EGF) by the type II activated macrophage. HB-EGF was 
originally identified in the culture supernatants of the U-937 macrophage like cell line
116
. 
It was found to be mitogenic for a number of cell types, including fibroblasts, smooth 
muscle cells, and a number of other cell types. HB-EGF is synthesized as a 
transmembrane precursor (proHBEGF) that can serve as a juxtacrine growth factor
117
, 
and in some species as the receptor for diphtheria toxin
118
. A number of proteases have 
been implicated as being responsible for ectodomain shedding, resulting in the formation 
of soluble HB-EGF (sHB-EGF). These include MMP3, MMP9, ADAM9, ADAM10, 
ADAM12, and ADAM17
119
. Recently, the metalloendopeptidase nardilysin (NRDc) was 
demonstrated to enhance ectodomain shedding by activation of ADAM17
120
. The 
resulting carboxy-terminal (membrane associated) fragment of proHB-EGF can 
contribute to cell cycle progression by translocating to the nucleus and interacting with 
promyelocytic leukemia zinc finger (PLZF), the transcriptional repressor of cyclin A
121
, 
or with Bcl6, the transcriptional repressor of cyclin D2
122
. sHB-EGF was shown 
originally to signal through the EGFR(ErbB1)
116




HB-EGF has been found to play a role in several normal physiological processes, 
including proper heart 
124
 and eyelid 
125
 formation and skin would healing by inducing 
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keratinocyte migration
126
. It has also been found to be associated with a number of 
pathological conditions. Macrophages, T-cells, and vascular smooth muscles cells 
(SMCs) of atherosclerotic plaques have been found to express HB-EGF
127,128
. 
Furthermore, not only is HB-EGF a potent mitogen for SMCs, but it also induces the 
expression of LOX-1, the receptor for oxidized LDL, by smooth muscle cells, potentially 




 HB-EGF has also been shown to be an important regulator of tumor growth and 
angiogenesis. In vitro, HB-EGF has been shown to increase the growth rate of tumor cells 
and to induce the expression of VEGF, and in vivo to strikingly increase angiogenic 
potential and tumorigenicity
130
. Recently, it was shown that HB-EGF may contribute to 
angiogenesis primarily by driving remodeling of vascular endothelial cells
131
. HB-EGF 
expression has been found to be enhanced in many tumors
119,132-134
. HB-EGF can also 
contribute to chemotherapy resistance. A number of chemotherapeutic agents, including 
SN38, doxorubicin, and cisplatin, rapidly induce the expression of HB-EGF in several 
tumor cell lines, as well as increase enzymatic shedding, resulting in strong EGFR 
activation and thus resistance to apoptosis 
135
. Bile acids, which have been implicated as 
cofactors of colon carcinogenesis, may mediate their activity through the upregulation 
and activation of MMP-7, resulting  in increased shedding of HB-EGF and thus 
proliferation of a human colon cancer cell line
136
.  
 Very little is known about the molecular regulation of HB-EGF. This is especially 
true for macrophages of which there are essentially no reports, despite the fact that HB-
EGF was originally characterized as a product of macrophages. There is some evidence 
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that the 3’-UTR may play a role in the accumulation of message. Sorensen et al. reported 
that use of the chemotherapeutic agent VP16 on the HeLa human cervical cancer cell line 
resulted in an increase in HB-EGF mRNA that could only be partially accounted for an 
increase in transcription. Instead, the increase in HB-EGF was found to be due to 
increased HB-EGF mRNA stability, which was contingent upon an 186bp region of the 
3’-UTR containing five AU-rich elements (ARE)
137
. In other systems, this has not been 
found to be a primary mechanism of increased HB-EGF mRNA induction. Ornskov et al. 
reported the induction of HB-EGF in RT4 bladder cancer cells was not due to increased 
stability, but due to a PI3K dependant increase in transcription
138
. In contrast, Ellis et al. 
reported that ERK and not PI3K or protein kinase C activity was required for HB-EGF 
induction in rat intestinal epithelial cells after scrape-wounding
139
. Similarly, HB-EGF 
induction was found to be due to ERK and the transcription factor Ets-2 in Ras/Raf 
transformed NIH 3T3 cells. Ets-2 was found to bind to a promoter element located at -
974/-988
140
. Additionally, the function of a number of tissue-specific transcription factors 
have been reported, including the intestinal-specific Cdx-2
141
 and MyoD, the family of 
transcription factors which regulate myogenesis
142
. Taken together, HB-EGF is a 
biologically significant growth factor whose regulation is only partially understood.  
  
Tumor Associated Macrophages 
 It is now a well accepted concept that tumor-associated macrophages (TAMs) can 
contribute to the progression of cancer instead of controlling it, apparently by a number 
of mechanisms. A number of studies have established a correlation between high TAM 
numbers and decreased patient survival. TAMs appear to contribute to tumor cell 
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proliferation and survival, invasion into surrounding healthy tissue, and metastasis to 
distal locations. Biswas et al. showed that resting TAMs constitutively expressed, among 
other things, high levels of immunosuppressive IL-10. Additionally, in vivo TAMs were 
found to produce IL-10 and were devoid of iNOS. Upon stimulation of TAMs in vitro, 
they expressed high levels of the immunosuppressive cytokines IL-10 and TGF-β while 
being defective in their expressive of inflammatory IL-1β, IL-6, and TNF-α
143
. In 
agreement with Cao et al., who showed that the NF-κBp50 homodimers suppressed 
inflammatory cytokine production while enhancing IL-10 production
101
, Saccani et al. 
recently showed that tumor-associated macrophages over-expressed p50 and this was 
responsible for the suppression of cytokines characteristic of classical activation of 
macrophages (IL-12, IL-6, TNF-α) and enhancement of IL-10 production. Importantly, 
tumor-associated macrophages from NF-κBp50
-/-
 mice had normal expression of 
inflammatory cytokines which correlated with reduced tumor growth
144
. Thus, it appears 
that overexpression of NF-κBp50 is one mechanism by which macrophages are driven to 
promote tumor growth. 
 Functionally, tumor-associated macrophages have a reduced ability to lyse tumor 
cells, present tumor antigens to T-cells, and as mentioned above, produce inflammatory 
cytokines. This has been attributed to a number of factors produced by tumors, including 
prostaglandin E2 (PGE2), IL-4, IL-10, and transforming growth factor-β (TGF-β). TAMs 
appear to play a number of functions to promote tumor progression. During early tumor 
development, macrophages aid in the invasion into healthy tissue due to their expression 
of a number of extracellular matrix modifying enzymes (e.g. matrix metalloproteinases, 
MMPs). Additionally, TAM infiltration has been shown to correlate with tumor cell 
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proliferation, which has been attributed to their production of epidermal growth factor 
(EGF), platelet-derived growth factor, TGF-β, hepatocyte growth factor, and basic 
fibroblast growth factor (bFGF). TAMs also migrate into hypoxic areas within tumors, 
where they induce new vasculature by producing a number a proangiogenic factors, most 
importantly vascular endothelial growth factor (VEGF). Lastly, TAMs appear to 
contribute to tumor metastasis. Movement of tumor cells away from the main tumor mass 
appears to be in juxtaposition with macrophages. Furthermore, migration of tumor cells 
into blood vessels generally occurs at clusters of macrophages. Thus, tumor metastasis 




Summary of Studies and Rationale  
 Previous studies in our lab made the observation that classical activating stimuli 
of macrophages combined with Fcγ-receptor ligation through IgG immune complexes 
results in a dramatic alteration in cytokine production. Macrophages now made high 
levels of anti-inflammatory IL-10 and low levels of inflammatory IL-12. The first part of 
these studies examines the functionality and biochemistry of these anti-inflammatory 
macrophages, herein known as Type II activated macrophages (MΦ-II). In the literature, 
these macrophages and macrophages populations that are not classically activated 
macrophages are known collectively as M2 cells. This work shows that type II activated 
macrophages are functionally distinct from other macrophage populations and therefore 
this terminology which combines all of these populations together may be inappropriate. 
We have begun to identify new markers for the MΦ-II that are not expressed on other 
populations.   
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 The second part of these studies focuses on the molecular regulation of heparin-
binding EGF-like growth factor (HB-EGF), a new marker for the MΦ-II with significant 
biological potential. Like IL-10, this factor is made in only modest quantities upon 
stimulation with LPS alone, whereas there is robust induction when this stimulation is 
combined with immune complexes. Additionally like IL-10, the MAP kinases are 
required for the production of HB-EGF, specifically the ERK1/2 and p38 pathways. ERK 
drives increased accessibility to the HB-EGF promoter, allowing for transcription factor 
binding. Additionally, 3 binding sites for the transcription factor Sp1 were identified 
within the HB-EGF promoter, with the site located at -83/-54 being required for the 
promoter’s activity. Finally, as there was a great deal of similarity in the regulation of 
HB-EGF and IL-10, we decided to investigate if other conditions which promote the 
production of IL-10 also promote the production of HB-EGF. Macrophages were 
stimulated with LPS in the presence of immune complexes, prostaglandin E2, 4T1 culture 
supernantants, and dB-cAMP. All of these conditions enhance endotoxin driven IL-10 
and also enhance HB-EGF production. Therefore, there appears to be a mechanism of 
coregulation. Lastly, as HB-EGF is an important growth factor in the contribution to both 
physiological and pathological conditions, such as cancer, and since IL-10 is produced in 
high quantities by tumor associated macrophages (TAMs), we investigated whether 
TAMs also produced high levels of HB-EGF.      
 The third part of these studies focuses on the molecular regulation of IL-10, 
specifically the potential histone kinases involved in its regulation and the role of PI3K. 
Histone phosphorylation at the IL-10 locus appear to drive increased accessibility to the 
promoter, allowing for transcription factor binding. We focused on the kinases MSK1 
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and MSK2, which the literature proposed to be kinases with the potential to 
phosphorylate histone H3 at serine 10 and serine 28. Preliminary data using siRNA 
supported the hypothesis that these kinases were required for the induction of IL-10. 
However, data using MSK1/2 double knockouts negated these findings. Additionally, 
PI3K appears to play a role in the regulation of IL-10. These preliminary studies were not 
completed, and form the basis for new projects in the lab.       
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CHAPTER 2: MATERIALS AND METHODS 
 
Mice  





-specific, DO11.10 TCRαβ mice were 
purchased from the Jackson Laboratory (Bar Harbor, Maine). Mice were used at 6-10 
weeks old as a source of bone marrow-derived macrophages (BMMΦ). All mice were 
maintained in HEPA-filtered Thoren units (Thoren Caging Systems) at the University of 
Maryland (College Park, MD). All procedures were reviewed and approved by the 
University of Maryland Institutional Animal Care and Use Committee.  
 
Reagents  
 The MEK/ERK inhibitor, U0126, p38 inhibitor, SB203580, JNK Inhibitor II, the 




(EMD Biosciences, San Diego, CA). Actinomycin D, 
cycloheximide, and dibutyryl cAMP were purchased from Sigma-Aldrich (St. Louis, 
MO). Macrophages were pre-treated with inhibitors 1 hour before stimulation at 
concentrations given within the figures or figure legends. ChIP-grade Anti-Sp1 and 
histone H3 antibodies were purchased from Upstate (Lake Placid, NY). TRIzol reagent 
and DNase I were purchased
 
from Invitrogen Life Technologies (Calsbad, CA). Klenow 
enzyme and restriction enzymes were purchased from New England Biolabs (Ipswich, 
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 BMMΦ were prepared as previously described
106
. Briefly, bone marrow was 
flushed from the femurs and tibias of mice with PBS+penicillin/streptomycin and cells 
were plated in petri dishes in DMEM/F12 supplemented with 10% FBS, 
penicillin/streptomycin, glutamine, and 20% conditioned medium from the supernatants 
of M-CSF secreting L929 (LC14) fibroblasts (LCCM). Cells were fed on day 2, and 
complete medium was replaced on day 6. Cells were used at 7-10 days for experiments. 
Macrophages were removed from Petri dishes using Cellstripper (Mediatech, Manassas, 
VA) and plated out into 48-well plates (2×10
5 
MΦ) for cytokine measurement and 6-well 
plates (2×10
6 
MΦ) for RNA isolation. Cells were cutured overnight in complete media 
without LCCM. 
 The RAW264.7 macrophage and 4T1 mammary tumor cell lines were obtained 
from the American Type Culture Collection (Manassas, VA). RAW264.7 cells were 
maintained in RPMI supplemented with 10% FBS,
 
penicillin/streptomycin, and 
glutamine.   
 
Macrophage Activation 
 For studies involving the characterization of macrophage populations, Ca-MΦ and 
MΦ-II were prepared by priming BMMΦ overnight with 100 U/ml recombinant IFN-γ 
(R&D Systems, Minneapolis, MN). Ca-MΦ were washed and stimulated with 10ng/ml 
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Ultra-Pure LPS (Escherichia
 
coli K12, Invivogen, San Diego, CA). MΦ-II received LPS 
along with immune complexes consisting of IgG-OVA. Immune complexes were made 
by mixing a tenfold molar excess of rabbit anti-OVA IgG (Cappel, Durham, NC) to OVA 
(Worthington, Lakewood, NJ) for 30 min at room temperature, as described
91
. AA-MΦ 




 For studies directed at the regulation of Heparin-Binding EGF-like Growth Factor 
(HB-EGF), unless otherwise noted, macrophages were not primed with IL-4 or IFN-γ 
Macrophages were simply activated with LPS or LPS + Immune complexes (IC), as 
described above. Any contaminating endotoxin was removed from the anti-OVA IgG 
prior to immune complex preparation using EndoClean from BioVitage, as previously 
described
105
. In some experiments, macrophages were stimulated with PGE-2 (10
-8
M), 
4T1 culture supernatants (27%), and 100µM dibutyryl cAMP in the presence or absence 
of LPS (10ng/ml). 
 
RT-PCR and Real-Time PCR 
 BMMΦ were subject to RNA
 
extraction using TRIzol reagent. The contaminating 
DNA was removed by DNase I treatment. ThermoScript RT-PCR
 
system (Invitrogen Life 
Technologies) was used to generate cDNA
 
from total RNA using oligo(dT)20 primers. 
Real-time PCR was conducted with the ABI Prism 7700 or Roche LightCycler 480 
sequence
 
detection system using iQ SYBR Green Supermix (Bio-Rad Laboratories,
 
Hurcules, CA) following the manufacturer’s instructions.
 
Standard PCR analysis was 
performed using Platinum PCR Supermix (Invitrogen Life Technologies). PCR was 
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performed using primer pairs specific for iNOS, Arginase-1 (Arg-1), Sphingosine 
Kinase-1 (SPHK1), FIZZ1, IL-10, IL12/23p40, HB-EGF, TNF-α, and GAPDH. These 
primer pairs are presented in Table 2. For data analysis, the CT value for GAPDH was 
used to normalize loading variations in the real-time PCRs. A ∆∆CT value was then 
obtained by subtracting control ∆CT values from the corresponding experimental ∆CT. 
The ∆∆CT values were converted to fold difference compared with the control by raising 
2 to the ∆∆CT power. 
 
Microarray analysis 
 RNA was prepared from 5×10
6
 classically activated or type II activated 
macrophages two hours after activation with LPS or LPS+Immune complexes (IC), 
respectively. High quality RNA was first purified using the TRIzol reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. RNA was then DNase 
(Roche, Indianapolis, IN) treated and purified using the RNeasy Mini kit (Qiagen, 
Valencia, CA), following the RNA cleanup protocol. RNA quality assessment and 
microarray analysis was performed at the University of Maryland Biotechnology 
Institute’s Microarray Core Facility. Microarray analysis was performed using the 
Affymetrix GeneChip Mouse Genome 430 2.0 (Santa Clara, CA) according to the 
manufacturers instructions. This array allowed for the assessment for changes in 
expression of approximately 39,000 transcripts. Robust changes in expression were 
determined according to the GeneChip Expression Analysis Data Analysis manual  
(Affymetrix), selecting for statistically significant changes in expression from Ca-MΦ 
(control) to MΦ-II (experimental). Briefly, robust changes from Ca-MΦ to MΦ-II had 






iNOS NM_010927 5’-CCCTTCCGAAGTTTCTGGCAGCAGC-3’ 
5’-GGCTGTCAGAGCCTCGTGGCTTTGG-3’ 
Arg-1 NM_007482 5’-CAGAAGAATGGAAGAGTCAG-3’  
5’-CAGATATGCAGGGAGTCACC-3’ 
SPHK1 NM_011451 5’-ACAGCAGTGTGCAGTTGATGA-3’  
5’-GGCAGTCATGTCCGGTGATG-3’ 
SPHK1a NM_011451 5’-CCATGTGGTGGTGTTGTGTT-3’ 
5’-CTTCCGTTCGGTGAGTATCAG-3’ 
SPHK1b NM_025367 5’-CCGCCGTTACCTCTAGCA-3’ 
5’-GGTTATCTCTGCCTCCTCCA-3’ 
FIZZ1 NM_020509 5’-GGTCCCAGTGCATATGGATGAGACCATAGA-3’ 
 5’-CACCTCTTCACTGCAGGGACAGTTGGCAGA-3’ 
IL-l0 NM_010548 5’-CCAGTTTTACCTGGTAGAAGTGATG-3’  
5’-TGTCTAGGTCCTGGAGTCCAGCAGACTCAA-3’ 
IL-l0 NM_010548 5'-AAGGACCAGCTGGACAACAT-3' 
5'-TCTCACCCAGGGAATTCAAA-3' 
(Real-Time PCR) 
IL-12/23p40 NM_008352 5’-ATGGCCATGTGGGAGCTGGAGAAAG-3’  
5’-GTGGAGCAGCAGATGTGAGTGGCT-3’ 




NM_019418 5’-CTGCATCAACGTCTTGGAGA-3’  
5’-GATACGTCAAGCCCCTCAAG-3’ 








Table 2: Polymerase chain reaction primers pairs used in both standard PCR and 
QRT-PCR analysis.   
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 a signal call of “P” or present and had statistically significant increases or decreases 
based on the detection and change algorithm, respectively, as determined by the 
Affymetrix Microarray Suite software. Robust changes also had a signal log ratio greater 
than 1 for increases. Two sets of biological replicates were compared for consistent 
robust changes. Details of these arrays as well as raw data have been deposited in NCBI's 
Gene Expression Omnibus (GEO, http://www. ncbi.nlm.nih.gov/geo) and are accessible 
through GEO dataset GDS2041. 
   
Immunoprecipitation and Western Blot Analysis 
 LIGHT/TNFSF14 was immunoprecipitated using 5µg of α-mouse LIGHT 
monoclonal antibody (R&D Systems, clone 261639) per ml of cell culture supernatant. 
Soluble heparin binding epidermal growth factor (HB-EGF) was immunoprecipitated 
using 5µg of polyclonal goat anti-mouse HB-EGF (M-18, Santa Cruz Biotechnology, 
CA) per ml of cell culture supernatant. Samples were subject to SDS-PAGE on 15% 
resolving gels and transferred to polyvinylidene difluoride membranes (Bio-Rad). 
Membranes were blotted with goat anti-mouse HB-EGF (1:200 dilution) or anti-mouse 
LIGHT monoclonal antibody and HRP-conjugated mouse anti-goat IgG secondary 
antibody or goat-α-Rat IgG secondary antibody (Santa Cruz), respectively. Membranes 
probing for HB-EGF were developed using ECL Western Blotting Detection Reagents 
(Amersham Biosciences, Buckinghamshire, England) according to the manufacturer’s 
instructions. Membranes probing for LIGHT were developed using Lumi-LightPLUS 
Western Blotting Substrate (Roche Diagnostics, Indianapolis, IN) according to the 
manufacturer’s instructions.    
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NO Production and Arginase Activity 
 NO production was estimated from the accumulation of NO2- in the medium after 
24 hours of macrophage activation using the Greiss reagent, as previously described
146
. 
Briefly, equal volumes of culture supernatant and Greiss reagent (100 µl) were mixed for 
10 minutes at room temperature. Absorbance at 540λ was measured with a Labsystems 
Multiscan Ascent assay plate reader. A solution of NO2 was used to construct a standard 
curve.  





 cells were washed and lysed with 100 µl of 0.1% TritonX-100, 16 hours after 
activation. Lysates were combined with 25mM Tris-HC1 and 1 mM MnCl2 and enzyme 
activated by heating for 10 mm at 55°C. The hydrolysis of arginine to ornithine and urea 
was conducted by incubating the lysates with 100 µl of 0.5M L-arginine (pH 9.7) at 37°C 
for 60 min. The reaction was stopped with 800 µl of H2SO4 (96%)/H3PO4 (85%)/H20 
(1/3/7, v/v/v). The urea concentration was measured at 550 nm after addition of 40 µl of 
α-isonitrosopropiophenone (9% solution in abs. ethanol) followed by heating at 100°C 
for 30 min.  
 
T-Cell Stimulation Assays 
 CD3
+
 T cells were prepared from the spleens of DO11.10 mice by negative 
selection using the SpinSep Mouse T Cell Enrichment Kit (StemCell Technologies Inc., 
Vancouver, BC.) according to the manufacturer’s instructions. For primary stimulation 
assays, 2×10
5
 macrophages were plated per well in 48-well plates and activated as 
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described above. Two hours following stimulation of macrophages, 5×10
5
 T cells were 
added to each well in a total volume of 0.550 ml RPMI 1640 (Cellgro, Herndon, VA) 
supplemented with 10% FCS, HEPES, Glutamine, Pen/Strep, and 50 µM 2- 
mercaptoethanol. For proliferation assays, cells were stained with CFSE 
(Invitrogen/Molecular Probes, Eugene, OR). Briefly, T cells were washed with PBS and 
resuspended at l×10
7
 cells/ml in 5 µM CFSE in PBS. Cells were stained while rocking for 
7 minutes, then quenched by adding an equal volume of FBS. Cells were washed an 
additional two times in complete media. For secondary stimulation assays, four days 
following the primary stimulation, fresh RPMI was added with 10 U/ml IL-2 (R&D 
Systems) to maintain cell viability. Seven days following the primary stimulation, cells 
were removed from culture, washed, counted, and added to immobilized anti-CD3 
(eBioscience, San Diego, CA), which was prepared by adding 5 µg/ml anti-CD3 to tissue 
culture dishes in PBS overnight. Cytokines were measured 24h later by either ELISA or 
Real-Time PCR or after 6 hours by intracellular staining.  
 
Cytokine Measurement by ELISA 
 Cytokine concentrations were measured by sandwich ELISA using the following 
capture and detection (biotinylated) antibody pairs from BD Pharmingen:  IL-12/23p40, 
C15.6 and Cl7.8; IL-10, JES5-2A5 and JES5-16E3; IFN-γ, R4-6A2, and XMG1.2; IL-4, 
11B11, and BVD6-24G2; TNF-α, G281-2626 and MP6-XT3 according to the 
manufacturer’s instructions. Concentrations were compared to a standard curve (0-
4000pg/ml) generated by serial dilution of recombinant protein standards purchased from 
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BD Pharmingen. Streptavidin alkaline phosphatase (AP) and p-nitrophenyl phosphate 
(PNPP) substrate were purchased from Southern Biotechnology (Birmingham, Alabama).  
 
Flow Cytometry and Intracellular Staining 
 Macrophages were stained with FITC conjugated α-I-A
d
 (AMS-32.1) or PE-
conjugated α-CD86 (GL1) (BD Pharmingen). T cells were stained with FITC-conjugated 
antibodies against CD25 (PC61), CD69 (H1.2F3), or CD62L (MEL-14) and a PE-
conjugated antibody against Thyl.2 (53-2.1) (eBioscience). CFSE-stained T cells were 
also stained against Thy1.2 for gating. Intracellular staining was performed on 
secondarily stimulated T cells using Pharmingen Cytofix/Cytoperm kit with GolgiStop 
according to the manufacturer’s instructions with some modifications. Briefly, cells were 
incubated in the presence of GolgiStop for 6 hours after reactivation. Cells were 
harvested, washed, and resuspended in Cytofix/Cytoperm solution for 20’ at 4°C, then 
washed in Perm/Wash solution. Cells were stained with a PE-conjugated antibody against 
IL-4 (11B11) and a FITC-conjugated antibody against IL-10 (JES5-16E3) (BD 
Pharmingen). Cells were analyzed on a Becton Dickinson FACSCalibur flow cytometer. 
Quadrants were set to an appropriate isotype control antibody for analysis. 
 
MTT Assay  
 MTT (1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan) assays were 
performed to measure changes in cell viability between macrophages stimulated with 
LPS or LPS+IC. 2×10
5
 BMMΦ were plated out overnight and stimulated for 24, 48, 72, 
and 96 hours in 500µl of media. At the specified time points, 250µl of media was 
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removed and 100µl of 5mg/ml of MTT (in PBS) was added and incubated at 37° for 2 
hours. The conversion of MTT to purple formazan was measured by lysing the cells for 
30 minutes at room temperature in 120µl of a solution of acidified isopropanol. Acidified 
isopropanol was prepared by adding 200µl of 2N HCl, 500µl of 10% SDS, and 300µl of 
water to 9ml of isopropanol. 100µl of cell lysate was then transferred to an assay plate 
and measured at 550λ. Each time point was performed in triplicate.  
 
RNA Stability Assay 
 2×10
6
 BMMΦ were stimulated for 2 hours with LPS or LPS+IC before the 
addition of actinomycin D to a final concentration of 0.5µg/ml. The degradation of HB-
EGF mRNA was subsequently measured by QRT-PCR over the following 2 hours. 
 
Electrophoretic Mobility Shift Assay  
Probes to amplify potential Sp1 binding sites were generated from the following 
oligo pairs. Consensus: 5’-CTGCGGGGCGGGGCA-3’ and 5’-TCTGCCCCGCCCC-3’; 
-348/-312: 5’-GGAAGGGGGCGGTGCCGGGCGGGGCGG and 5’-
GGAGCCCCGCCCCGCCCGGCACCGCCCCC-3’; -1277/-1258: 5’-
AAGTGGGGGTGGGGTG-3’ and 5’- TCTCCACCCCACCCCC-3’; and -1828/-1809: 
5’-CCCCACCCCCACCCCC-3’ and 5’- CCCTGGGGGTGGGGGT-3’. Oligo pairs were 
combined at an equal molar ratio and annealed by heating to >95°C in a heating block 
then allowed to cool to room temperature over several hours. Probes were then 
radiolabeled using α-
32
P dGTP by the Klenow fill-in method.
 
Nuclear extracts were 
prepared from 1×10
7
 RAW264.7 cells as previously described
101
. Briefly, RAW264.7 
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cells were stimulated for 45’, washed twice with ice-cold PBS, then scraped from dishes 
and the cells pelleted by centrifugation. Nuclei were isolated by resuspending cells in 
400µl of nuclei isolation buffer (10mM HEPES pH7.9, 10mM KCl, 0.1mM EDTA, 
0.1mM EGTA, 1mM DTT, 0.5mM PMSF, 10µg/ml aprotinin, and 10µg/ml leupeptin) 
and incubating on ice for 15 minutes. 25µl of NP-40 was then added and nuclei pelleted 
by centrifugation at 12,000g for 40 seconds. Nuclei were washed with an additional 
200µl of nuclei isolation buffer, then nuclear proteins extracted using 100µl of extraction 
buffer (20mM HEPES, 0.4M NaCl, 1mM EGTA, 1mM EDTA, 25% glycerol, 1mM 
DTT, 0.5mM PMSF, 10µg/ml aprotinin, and 10µg/ml leupeptin) and incubated on ice for 
30 minutes. Insoluble nuclear material was then pelleted by centrifugation for 10 minutes 
at 14,000 RPM and supernatants containing soluble nuclear proteins collected. 
32
P 
labeled double-stranded oligomers were incubated on ice for 1h with nuclear extracts, 
poly(DiDc), and BSA. Binding was competed with increasing concentrations (10×-50×) 
of cold unlabeled probe or consensus cold probe. DNA-Sp1 protein complexes were 
supershifted by incubating nuclear extracts with 1 or 3µg of antibody against Sp1 or 
Histone H3 for 30’ on ice prior to incubation with labeled probe. DNA/Protein mixtures 
were run on 6% Acrylamide/0.25%TBE gels which were pre-run for one hour prior to 
loading.  
  
Chromatin Immunoprecipitation (ChIP) Assay 
ChIP assays were conducted using the ChIP Assay kit (Upstate Biotechnology) 
following
 
the manufacturer’s protocol with some modifications, as previously 
described
105
. Briefly, approximately 1×10
7
 BMMΦ were stimulated in 100mm tissue 
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culture dishes for the time indicated in the figures, then fixed with formaldehyde at a final 
concentration of 1% for 10-15 minutes at room temperature. Cells were thoroughly 
washed with PBS containing protease and phosphatase inhibitors, then scraped and 
centrifuged. Fixed cells were resuspended in SDS lysis buffer containing inhibitors at a 
concentration of 10
7
cells/ml and allowed to lyse on ice for 10 minutes. Lysed cells were 
separated into 200µl aliquots then DNA was sheared using a Cole Palmer ultrasonic 
processor (Cole-Parmer Instrument Company,Vernon Hills, IL). This resulted in 




Aliquots of the same 
time points were combined and diluted in ChIP dilution buffer. The remaining protocol of 
immunoprecipitation, washing, and elution, and purification of DNA was followed 
according to the manufacturer’s protocol. HB-EGF (NC_000084) promoter primers used 
for ChIP analysis are presented in Table 4 (Chapter 4). 
 
DNase Accessibility Assay 





BMMΦ grown on 100mm tissue culture dished were stimulated with LPS+IC for 
the indicated times, then fixed with formaldehyde at a final concentration of 1%. Cells 
were thoroughly washed and scraped into cold PBS, then lysed in ice-cold Nuclei EZ 
lysis buffer (Sigma-Aldrich). Washed nuclei were resuspended in ice-cold DNase I buffer 
(100 mM NaCl, 50
 
mM Tris, pH 8.0, 3 mM MgCl2, 0.15 mM spermine, and 0.5 mM 
spermidine)
 
supplemented with 1 mM CaCl2. DNase I (Roche Diagnostics) was
 
added 
and incubated on ice for 1 hour. The reaction was stopped by adding DNase stop buffer 
(10mM EDTA, 20% SDS, and 0.4 M NaCl) and cross linking was reversed by incubation 
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at 65° for approximately 4 hours. Proteinase K and RNase A were added at 37° 
overnight. DNA was then purified by phenol/chloroform extraction and cold ethanol 
precipitation.  
 
HB-EGF Promoter Reporter Construct 
Approximately 3kb of the HB-EGF promoter was cloned using the following 
primers: Forward 5’-ACCTCGGAGACATGAGCTCTTAC-3’ and reverse 5’-
GCTACCCTCTCAATGAATTAAGCTA-3’. PCR was performed using Expand Long 
Template PCR System (Roche Diagnostics). The PCR product was ligated into the 
pCRII-TOPO vector (Invitrogen) for scale up. The cloned promoter fragment (-
2704/+330, relative to transcriptional start site) was removed using NheI and EcoRV 
restriction enzymes, gel purified, then ligated into the pGL4.19[luc2CP/Neo] luciferase 
reporter vector (Promega Corporation, Madison, WI). The -1238/+330 promoter 
construct was made by KpnI digestion of the -2704/+330 construct, gel purification of the 
larger fragment and ligation. The -557/+330 promoter construct was made by digestion of 
the -2704/+330 construct with Tth111I and NheI restriction enzymes. The larger 
fragment was then gel purified and sticky ends were filled in using Klenow enzyme. The 
resultant fragment was then blunt-end ligated (Figure 7).  
 Mutation of the Sp1 site in the -557/+330 promoter construct was done using the 
QuikChange Site-Directed Mutagenesis kit II from Stratagene (La Jolla, CA) according 
to the manufacturer’s instructions. The following primers were designed using 
Stratagene’s QuikChange primer design program; Sense: 5’- 
GGGAGGGAAGGGGTAGGTGCCGGTAGGGTAGGGGCTCCCACTC-3’ and 






































Figure 7: HB-EGF promoter luciferase plasmids. 
(A) 3.0kb HB-EGF luciferase construct containing relevant restriction enzyme sites used 
in the construction and validation of 1.5kb and 0.9kb reporter plasmids. 1.5kb promoter 
plasmid was constructed by KpnI digestion followed by sticky-end ligation. 0.9kb 
promoter plasmid was constructed by NheI and Tht111l digestion, klenow fill-in, then 
blunt-end ligation. (B) Restriction enzyme analysis for validation of HB-EGF reporter 
constructs. 3.0kb and 1.5kb were digested using NheI and HindIII. 0.9kb was digested 
using KpnI and HindIII.   
1.       2.       3.      4.
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antisense: 5’-GAGTGGGAGCCCCTACCCTACCGGCACCTACCCCTTCCCTCCC. 
Mutations were confirmed by sequencing (Genewiz, Inc., South Plainfield, NJ).  
 
Transient Transfection and Luciferase Activity  
 RAW264.7 cells were transiently transfected using the FuGENE HD transfection 
reagent according to the manufacturer’s instructions. Briefly, 2µg of plasmid was added 
to 3µg of FuGENE diluted in 100µl of RPMI and incubated at room temperature for 
30minutes. 20µl of the resultant transfection complex was added per well of a 48-well 
plate containing approximately 2×10
5
 RAW cells. Each reporter construct was 
cotransfected with the pRL-Null Renilla luciferase plasmid at a ratio of 40:1.The 
following morning, media was replaced and cells were stimulated according to the figure 
for approximately 8 hours. Luciferase activity was assessed using the Dual-Luciferase 
Reporter Assay System (Promega). Firefly luciferase activity was measured for each HB-
EGF reporter construct and normalized using Renilla luciferase activity. 
 
5’ Rapid Amplification of cDNA Ends (RACE) for HB-EGF 
 5’ RACE was performed using the FirstChoice RLM-RACE from Ambion 
(Austin, Texas) according to the manufacturer’s instructions using total RNA from 120’ 
LPS+IC stimulated macrophages. Briefly, total RNA was treated with calf intestinal 
alkaline phosphatase to remove free 5’-phosphates from nucleic acids lacking a 5’ cap. 
The 5’ cap was then removed using tobacco acid pyrophosphatase. A RACE adaptor 
oligonucleotide was then ligated to the 5’ end of full length RNA and reverse 
transcription performed. A nested PCR reaction was performed using RACE adaptor-
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specific (provided) and HB-EGF specific oligonucleotides. The reverse (HB-EGF 
specific) oligonucleotides used were: (outer primer) 
5’GGCATTTGCAAGAGGGAGTA-3’ and (inner primer) 5'- 
GTGGGTAGCAGCTGGTTTGT-3'. The nested PCR reaction was attempted using the 
Fast Start High Fidelity PCR System (Roche, Mannheim, Germany) or Platinum PCR 
Supermix High Fidelity from Invitrogen, which were unsuccessful and successful, 
respectively. These PCR reactions are presented in Figure25A and labeled PCR 1-1 and 
1-2 for the Fast Start High Fidelity PCR System and PCR 2-1 and 2-2 for the Platinum 
PCR Supermix High Fidelity. The nested PCR reaction 2-2 produced a major band of the 
expected length of approximately 450bp. The PCR product was directly ligated into the 
pCR4-TOPO plasmid using the TOPO TA cloning kit for sequencing from Invitrogen 
and transformed into Top10 chemically competent E. coli. Restriction digestion of clones 
with EcoRI revealed clones of three sizes, (Figure 25B) all of which were sequenced.    
 
Tumor Associated Macrophage Isolation 
 Tumor associated macrophages were isolated from 15-20mm tumors. Tumors 
were excised from the hind leg of the mice and physically disrupted in a filter sterilized 
solution of RPMI containing 0.3% Type IV Collagenase (Worthington) and 200mg/ml 
DNase (Roche). Enzyme digestion of finely minced tumors was allowed to proceed for 
approximately 30’-45’ at 37°C. Digested tumor was diluted in RPMI and passed through 
a 100µM nylon filter into a 50ml tube. After centrifugation, cells were resuspended in 
ACK lysis buffer to lyse contaminating red blood cells, then centrifuged and resuspended 
in RPMI and plated out onto ten 100mm tissue culture dishes. Cells were incubated for 1 
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hour at 37°C to select for adherent cells. Tissue culture dishes were thoroughly washed 
five times with warm RPMI and adherent cells were removed using CellStripper. 
Adherent cells were then counted and stained with PerCP-Cy5.5 α-CD11b (Clone 
M1/70) and FITC α-F4/80 (Clone BM8). Double positive cells were then sorted and 
allowed to recover for 1 hour at 37°C prior to stimulation. 
 
Immunoprecipitation Kinase Assay 
 Immunoprecipitation kinase assays were performed similar to Upstate’s 
immunoprecipitation radioactive kinase assay protocol, without using radioactivity. 
2×10
6
 cells were plated overnight then given immune complexes with or without LPS or 
left unstimulated for times indicated in figure 37. Cells were then washed with cold PBS 
and lysed with 200µl buffer A (50 mM Tris-HCl, ph 7.5, 1mM EDTA, 1mM EGTA, 
0.1% (v/v) 2-metcaptoethanol, 1% Triton X-100, 5-mM) supplemented with a protease 
inhibitor cocktail (Roche) and phosphatase inhibitors (5mM sodium pyrophosphate, 
0.5mM NaV, 50mM NaF, 10mM β-glycerophosphate). Insoluble material was removed 
by centrifugation for 10’ at 10,000 RPM and lysates pre-cleared with Protein G-PLUS 
Agarose (Santa Cruz). 50µl of precleared cell lysate was added to 200µl of buffer A with 
5µg of anti-MSK1 or anti-MSK2 at 4
o
C overnight. MSK-Ab complex was precipitated by 
adding 100µl of 25% Protein G-PLUS Agarose slurry at 4
o
C for 2 hours. Agarose beads 
were washed two times with buffer A then with assay dilution buffer I (20mM MOPS, 
pH 7.2, 5mM EGTA, 25mM β-glycerophosphate, 1mM NaVO4 and 1mM dithiothreitol). 
 Beads were then resuspended in assay 20µl of ADBI, then 10µl of 500µM ATP 
and 10µl of 200 µg/ml recombinant human histone H3 (Upstate) was added. This was 
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then incubated at 30°C for 15 minutes with agitation every 5 minutes. The reaction was 
terminated by spinning down beads and adding supernatants to an equal volume of 2x 
sample buffer then boiling for 3 minutes. Samples were subject to PAGE and blotted for 
anti-phosphorylated histone H3 (S10). 
 
siRNA Design and Transfection 
 Potential siRNA targets were found using Ambion’s online siRNA target finder 
and the corresponding sense and antisense siRNA oligonucleotides used for the 
Silencer™ in vitro siRNA Construction Kit (Ambion) were designed. siRNAs were 
constructed according to the manufacturer’s instructions. Briefly, two 29-mer DNA 
template oligonucleotides consisting of 21 nucleotides encoding the siRNA and 8 
nucleotides complementary to the T7 Promoter Primer were annealed to the T7 promoter 
primer and filled in with DNA polymerase. Sense and antisense templates were 
transcribed by T7 RNA polymerase. These RNA transcripts were hybridized to create 
dsRNA. Leader sequences were removed using single-strand RNase and DNA templates 
removed with DNase and the remaining dsRNA purified. The resultant product is double 
stranded 21-mer. The following oligonucleotides were used to construct siRNAs for 






 macrophages cultured for 6 or 7 days were used for each transfection. 
Macrophages were resuspended in 100µl of Cell Line Kit T transfection solution 
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(Amaxa) with 1µl of 10µM (100nM final concentration) dsRNA. This suspension was 
added to transfection cuvettes and transfected with the Amaxa’s nucleofector device 
(program T20). Cells were resuspended in warm media containing growth factors and 
then cell yield was determined. Cells were then added to preincubated media and cultured 
for 24 hours. Additional media was added and cultured for an additional 24 hours before 
silencing efficiency was determined by RT-PCR and cells assayed for cytokine 
production.  
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CHAPTER 3: CHARACTERIZATION OF THREE ACTIVATED 
MACROPHAGE POPULATIONS 
 
Activated macrophages differ in cytokine production 
 We generated three distinct populations of activated macrophages in vitro from 
murine bone-marrow derived macrophages, and performed a series of parallel 
comparisons between them.  As a first step, we measured cytokine production from each 
of these cells.  Classically activated macrophages have long been associated with the 
secretion of IL-12
148
, whereas MΦ-II were previously shown by the lab to produce high 
amounts of IL-10
92
.  Others have also suggested that the AA-MΦ were also a good source 
of IL-10
149
. Cytokine production from these three populations of macrophages was 
compared.  Ca-MΦ produced relatively high levels of IL-12/23P40 but low levels of IL-
l0 (Figure 8A).  Coupling macrophage activation with FcγR ligation by the addition of 
immune complexes (IC) resulted in a population of macrophages (MΦ-II) that produced 
high levels of IL-10 and low levels of IL-12/23p40 (Figure 8A), as previously reported
90
. 
Priming of these cells with IFN-γ was not necessary to see this reciprocal alteration in 
cytokine production caused by the addition of IC (Figure 8B).    
IL-4 treated macrophages (AA-MΦ) failed to secrete detectable levels of either 
IL-12/23p40 or IL-10 (Figure 8A).  Cytokine production by AA-MΦ was not 
significantly different from unstimulated macrophages. Because previous studies reported 
that macrophages isolated from infections in which IL-4 predominated were a rich source 
of IL-10
150
, we primed macrophages with IL-4 overnight and then stimulated them with 
LPS the next morning and examined cytokine production. The stimulation of IL-4-primed  
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Figure 8: Cytokine profiles of activated macrophages.  
(A)  IL-10 (hatched bars, left axis) and IL-12/23p40 (solid bars, right) were measured by 
ELISA 16 h after macrophage activation. AA-MΦ were prepared by treating 
macrophages overnight with IL-4 (10U/ml). Ca-MΦ and MΦ-II were prepared by treated 
macrophages with IFN-γ (100U/ml) overnight, then stimulating with LPS or LPS/IC, 
respectively. (B) IL-10 (hatched bars) and IL-12/23P40 (black bars) levels in 
supernatants following a 16 hr stimulation of cells with LPS or LPS/IC. These cells were 
not primed with IFN-γ. (C) IL-10 levels in macrophages primed overnight with IFN-γ or 
IL-4, then left unstimulated or stimulated with immune complexes(IC), LPS, or LPS/IC.  
Figures are representative of at least three independent experiments. Error bars indicate 
mean± SD. *p<0.001 
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cells with LPS resulted in a modest increase in the production of IL-10 (Figure 8C).  
However, the level of this cytokine remained substantially below that of MΦ-II.  IL-4 
primed cells were also stimulated with LPS+IC. These IL-4 primed cells also responded 
to the addition of IC by secreting high levels of IL-10 (Figure 8C).  Thus, all three 
populations of activated macrophages display distinct profiles of cytokine production, 
and yet these cells exhibit functional plasticity. Thus, the nature, order, and/or duration of 




Activated macrophages exhibit different patterns of arginine metabolism  
Alterations in arginine metabolism have previously been described as one of the 
defining characteristics of murine alternatively activated macrophages. Therefore, we 
examined iNOS and arginase production in each of the three macrophage populations. 
First we measured the accumulation of NO2
-
 in culture supernatants by the Greiss 
assay
146
. Both Ca-MΦ and MΦ-II produced relatively high levels of NO, whereas the 
AA-MΦ produced virtually no detectable NO (Figure 9A). We also measured the amount 
of urea generated by these three populations of macrophages. Ca-MΦ and MΦ-II 
possessed virtually no arginase activity above that of the basal level associated with 
unstimulated macrophages, therefore were unable to produce appreciable urea when 
lysates were incubated with L-arginine. The opposite was true of the AA-MΦ which 
produced high levels of urea (Figure 9B). Thus, with regard to arginine metabolism, AA-
MΦ were distinct from the other two populations of macrophages.  AA-MΦ failed to 
produce NO but readily catabolized arginine to urea, whereas the converse was true for 
Ca-MΦ and MΦ-II (Figure 9).   
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Figure 9: Activated macrophages exhibit different patterns of arginine metabolism. 
(A) NO2
-
 accumulation after 24 hours of macrophage activation measuring iNOS activity. 
Equal volumes of cell supernatants were mixed with Greiss regeant for 10 minutes, and 
the absorbance at 540λ was measured. A solution of NO2
-
 was used to construct a 
standard curve. (B) Arginase assay measuring the formation of urea after incubation of 
lysates from activated macrophages with arginine. Arginase enzyme was activated by 
heating for 10’ at 55°C. The hydrolysis of arginine to ornithine and urea was conducted 
by incubating the lysates with L-arginine at 37°C for 60 min. The reaction was stopped 
and urea measured at 550 nm after addition of α-isonitrosopropiophenone followed by 
heating at 100°C for 30 min. Values were compared to a standard curve of urea 
concentrations. Figures are representative of at least three independent experiments. Error 
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Biochemical Markers to discriminate between populations of macrophages   
RNA was isolated from the three populations of activated macrophages 4 hours 
after stimulation, and analyzed by RT-PCR (Figure 10). We first examined iNOS and 
Arg-1 mRNA in each of the three populations. As previously reported, and consistent 
with the protein activity data above, macrophages exposed to the Th2 associated cytokine 
IL-4 produced mRNA for arginase but failed to produce iNOS mRNA
152
. Conversely, 
Ca-MΦ and MΦ-II express iNOS mRNA, but fail to express appreciable arginase (Figure 
10).  Ca-MΦ produce high levels of IL-12/23p40 but little detectable IL-10, whereas 
MΦ-II express high levels of IL-10 and less IL-12/23p40. Only the AA-MΦ expressed 
the previously described marker FIZZ1, a secreted protein that has been associated with 
allergic and pulmonary inflammation
153,154
, confirming that FIZZ1 represents a reliable 
marker for murine AA-MΦ (Figure 10).   
Since there have been no reported markers for MΦ-II we performed an initial 
microarray analysis using the Affimetrix GeneChip Mouse Genome 430 2.0.  The 
analysis included a comparison between Ca-MΦ and MΦ-II, since these two populations 
of cells exhibited several biochemical similarities (Figure 10).  Microarray analysis 
revealed a limited number of changes in gene expression between these two cell types.   
When a 2-fold difference in transcript levels was used as the cut-off, only 184 of the 
39,000 possible transcripts represented on this chip (<0.5%) were consistently increased 
in MΦ-II relative to Ca-MΦ.  Table 3 lists 29 genes of known biological function which 
were increased by 3-fold or more in MΦ-II, and which had a signal greater than 2000.  
These 29 genes are the only ones that fit these criteria.  The data discussed in this 
publication have been deposited in NCBI's Gene Expression Omnibus (GEO,  






















Figure 10: Activated macrophages have different mRNA expression profiles.  
RT-PCR was performed to examine the expression of iNOS, Arg-1, SPHK-1, FIZZ1, IL-
10, and IL-12/23p40 mRNA levels in four different macrophage populations. cDNA from 
unstimulated macrophages and the three activated macrophage populations, was reverse 
transcribed from total RNA four hours after stimulation. GAPDH mRNA was used to 
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Bcar3 breast cancer anti-estrogen resistance 3 3479.25 3.031 
Bhlhb2 basic helix-loop-helix domain containing, class B, 2 2579.85 4.203 
Dusp4 dual specificity phosphatase 4 2713.25 3.375 
Emp1 epithelial membrane protein 1 6476.5 4.297 
Fabp4 fatty acid binding protein 4 5134.4 7.222 
Fosb FBJ osteosarcoma oncogene B 2357.35 3.711 
Gadd45g growth arrest and DNA-damage-inducible 45 gamma 2487.2 5.78 
Gas2l3 growth arrest-specific 2 like 3 6283.1 5.291 
Hbegf heparin-binding EGF-like growth factor 6600.95 7.956 
Hmox1 heme oxygenase (decycling) 1 2805.8 4.297 
Ifnb1 interferon beta 1 3703.8 3.186 
Il10 interleukin 10 12817.6 3.249 
Impact imprinted and ancient 2049.6 3.516 
Klf9 Kruppel-like factor 9 2844.65 3.639 
Mafb v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein B 
3254.3 4.76 
Ndrg1 N-myc downstream regulated gene 1 8642.7 3.28 
Ndrl N-myc downstream regulated-like 6851.45 3.186 
Plau plasminogen activator, urokinase 5734.55 3.155 
Plk2 polo-like kinase 2 3925.6 6.981 
Rgc32 response gene to complement 32 2356.9 6.28 
Rhov ras homolog gene family, member V 4564.9 7.423 
Ris2 (cdt1) chromatin licensing and DNA replication factor 1 3508.2 3.14 
Samd8 sterile alpha motif domain containing 8 2713.4 3.155 
Sgk serum/glucocorticoid regulated kinase 1 6724.3 3.155 
Slc6a8 solute carrier family 6 (neurotransmitter transporter, 
creatine), member 8 
2382.25 3.015 
Snx30 sorting nexin family member 30 6079.5 4.06 
Sphk1 sphingosine kinase 1 2449.95 3.257 
Tnfsf14 tumor necrosis factor (ligand) superfamily, member 14 2281.05 8.657 
Vps18 vacuolar protein sorting 18 5875.6 4.972 
 
Table 3: Increases in gene expression in MΦ-II relative to Ca-MΦ. Includes genes with 
known biological function that exhibited a signal greater than 2000 and an average fold 
change of 3 or more. 
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 number GSE4811. 
 From this analysis, several genes that were up-regulated in MΦ-II were examined.  
Sphingosine kinase-1 was shown to be upregulated by more than 3-fold in MΦ-II, 
relative to Ca-MΦ at 2 h poststimulation.  We therefore compared SPHK-1 mRNA levels 
in the three macrophage populations. Only the Type II activated macrophages expressed 
detectable levels of SPHK-1 mRNA by conventional PCR four hours after stimulation 
(Figure 10). This observation was extended by quantitative real-time PCR (QRT-PCR) 
(Figure 11A). This analysis revealed that SPHK-1 mRNA was robustly induced in MΦ-
II, with mRNA levels increasing substantially over time, relative to unstimulated cells 
(Figure 11A). There was some induction of SPHK-1 mRNA in Ca-MΦ, however this 
induction was modest relative to MΦ-II. Thus, high SPHK-1 expression may be useful to 
identify MΦ-II in tissue.    
 Since mice have two forms of sphingosine kinase-1, SPHK1a and SPHK1b, we 
decided to determine which of these two isoforms was up-regulated by the type II 
activated macrophage. These isoforms differ in both in their enzymatic activity, but also 
in their characteristics. The SPHK1a exhibits higher enzymatic activity, stability, and is 
localized to the cytoplasm, while SPHK1b is relatively unstable and localized to 
membrane fractions
155,156
. The expression of SPHK1 was monitored by isoform specific 
primers after stimulation with LPS or LPS+IC (Figure 12). The expression of SPHK1a 
was strongly induced after stimulation with LPS+IC, whereas there was a relatively 
modest increase after stimulation with LPS alone (Figure 12A). Neither stimulation 
condition resulted in an appreciable change in the expression of SPHK1b (Figure 12B). 
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Figure 11: Type-II activated macrophages upregulate sphingosine kinase-1 (SPHK-
1) and TNFSF14/LIGHT. 
(A) SPHK-1 mRNA was measured by QRT-PCR after macrophage activation by LPS 
(closed circles), LPS and immune complexes (LPS/IC, closed triangles), or IL-4 (open 
circles). (B) Relative LIGHT mRNA was measured by QRT-PCR after macrophage 
activation by LPS (closed circles), LPS/IC (closed triangles), or IL-4 (open circles). Fold 
values are relative to unstimulated control. (C) Immunoprecipitation of soluble LIGHT 
from 6h cell supernatants of unstimulated macrophages, Ca-MΦ, and MΦ-II. Western 
blot analysis for LIGHT using a rat α-LIGHT monoclonal antibody, showing the soluble 
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Figure 12: Expression of Sphingosine Kinase-1 splice variants SPHK1a and 
SPHK1b. 
Macrophages were stimulated with LPS or LPS+IC and relative SPHK1a (A) and 
SPHK1b (B) mRNA levels were measured by QRT-PCR after 0’, 30’, 60’, 120’, 180’, 
and 240’. Values are relative to mRNA levels present at 0’. Figures are representative of 
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Type II Activated Macrophages express LIGHT, a member of the TNF superfamily   
 From the microarray analysis, another marker for MΦ-II emerged. This was 
murine LIGHT or TNFSF14. It was found to be present at more than 8.5-fold higher 
levels in the MΦ-II relative to Ca-MΦ. In order to confirm LIGHT mRNA induction in 
MΦ-II, QRT-PCR was performed to compare mRNA levels in the three macrophage 
populations. In the MΦ-II, LIGHT mRNA increased by approximately 200-fold over 
unstimulated cells, peaking at 2 hours post-stimulation (Figure 11B). Classically 
activated macrophages had a slight induction of LIGHT mRNA, but these levels were 
always at least 10-fold lower than these observed in MΦ-II (Figure 11B). There was no 
evidence for LIGHT induction in AA-MΦ and in fact the addition of IL-4 marginally 
decreased LIGHT mRNA levels in AA-MΦ. 
 It has previously been reported that LIGHT may be secreted or cleaved from the 
surface of cells in a soluble form. In order to address this possibility, macrophages were 
primed with IFN-γ, and then stimulated for 6 hours with LPS or LPS+I.C. IL-4 treated 
macrophages were not addressed because the expression of LIGHT was not induced in 
this population (Figure 11b). LIGHT was then immunoprecipitated from the supernatants 
of stimulated cells with a monoclonal antibody specific for the extracellular domain of 
LIGHT. A ~20-25 kD band, which corresponds to the molecular mass of soluble LIGHT 
(sLIGHT), was detected only in the supernatants of MΦ-II (Figure 11C). This suggests 
that MΦ-II are the primary macrophage producers of LIGHT, and that this molecule is 
either rapidly cleaved from the surface of these cells or secreted as soluble LIGHT by 
MΦ-II. 
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Figure 13: Macrophages stimulated with LPS+IC retain viability. 
MTT assays were performed to measure the conversion of MTT to purple formazan. 
2×10
5
 BMMΦ were stimulated with LPS or LPS/IC, then assayed every 24 hours. For 
each time point, macrophages were incubated with MTT for 2 hours, lysed, then 
absorbance measured at 550λ. Each time point was performed in triplicate and 
normalized to the absorbance at 24 hours. Asterisk indicates p<0.001.   
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Type II Activated Macrophages Retain Long-Term Viability 
 It has previously been reported that the induction of sphingosine kinase is 
important for retaining cell viability in endotoxin stimulated macrophages. In these 
studies, the use of a sphingosine kinase specific siRNA sensitized the macrophage cell 
line RAW264.7 cells, as well as primary macrophages to LPS-induced apoptosis
157
. As 
we see relatively high induction of sphingosine kinase in macrophages stimulated with 
LPS+IC, we wanted to address whether stimulation of macrophages in the presence of 
immune complexes enhances the viability of macrophages over LPS stimulated cells. 
Macrophages were stimulated with LPS or LPS+IC for a 24, 48, 72, or 96 hours. Changes 
in cell viability were measured by MTT conversion to formazan (Figure 13). Over this 
period of time, macrophages stimulated with LPS lost viability. However, when 
macrophages were stimulated with LPS+IC, they retained their viability over 96 hours 
(Figure 13). Although this is certainly not definitive, the induction of sphingosine kinase 
by MΦ-II may contribute to sustained viability of these cells. 
 
Antigen presentation by activated macrophages  
Activated macrophages are able to present antigen to T cells
91
. We wished to 
examine the antigen presenting potential of each of the three macrophage populations.  
One of the defining characteristics of efficient APCs is the expression of MHC class II 
and B7 costimulatory molecules. BMMΦ were primed with IFN-γ overnight or left 
unprimed.  Primed cells were then stimulated for 24 hours with LPS (Ca-MΦ), or LPS + 
IgG-OVA immune complexes (MΦ-II).  AA-MΦ were stimulated with IL-4. These cells  
were then stained with FITC-conjugated α-I-A
d
 or PE-conjugated α-CD86.  Expression 






























Figure 14: Activated macrophages express different levels of MHC class II and B7 
costimulatory molecules. 
Flow cytometry profiles for (A) MHC class II and (B) B7.2 (CD86) on activated 
macrophages 24 hours after stimulation. Macrophages were primed with IFN-γ and 
stimulated with LPS (Ca-MΦ) or LPS+IC (MΦ-II), primed with IL-4 (AA-MΦ), or left 
unstimulated (Uns. MΦ). Macrophages were stained with FITC conjugated α-I-A
d
 or PE-
conjugated α-CD86. Changes in expression are assessed by comparison against 
unstimulated macrophages.  Figures are representative of at least three independent 
experiments. 
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 in activated cells was compared to that of unstimulated macrophages. MΦ-II had the 
highest expression of MHC class II (Figure 14A) and CD86 (Figure 14B). Ca-MΦ also 
up-regulated MHC class II and CD86, although not to the level of MΦ-II. In contrast, 
AA-MΦ only minimally up-regulated MHC class II and CD86 expression. Thus, the 
three macrophage populations express distinct levels of these molecules and therefore 
may have different potential to present antigen to T cells.   
Each of the macrophage populations were analyzed for their ability to present 
ovalbumin antigen (OVA) to naïve OVA-specific DO11.10 T cells. For these studies 
BMMΦ were primed overnight with IFN-γ (100 U/ml) or IL-4 (10 U/ml, AA-MΦ). Cells 
primed with IL-4 overnight were confirmed to have high arginase and FIZZ1 expression 
(data not shown). Cells were washed and stimulated with LPS+OVA (Ca-MΦ), or 
LPS+IgG-OVA (MΦ-II), or OVA alone (AA-MΦ and unstimulated macrophages). CD3
+
 
T cells were isolated from total splenocytes from DO11.10 mice and added to 
macrophages 2 hours after activation. T cells and macrophages were co-cultured for 24 
hours, and then stained for CD25, CD69, and CD62L expression. CD25 and CD69 
typically increase with T cell activation, whereas CD62L decreases
158-160
. The expression 
of each marker was assessed by flow cytometry, gating on Thyl.2
+
 cells. As expected, 
unstimulated macrophages were poor APCs, driving minimal up-regulation of CD25 
(Figure 15, left panels) and CD69 (Figure 15, center panels) by T cells.  They also 
induced only minimal down-regulation of CD62L (Figure 15, right panels). T cells co-
cultured with MΦ-II showed the greatest signs of activation, expressing the highest levels  
of CD25 and CD69 expression and the lowest expression of CD62L (Figure 15). Thus, 
despite the potent production of IL-10 from MΦ-II, these cells are very effective 


























Figure 15: Activated macrophages drive different levels of T cell activation. 
DO11.10 T-cells were stained after 24 hours of co-culture with unstimulated (top panels), 
alternatively activated (upper middle panels), classically activated (lower middle panels), 
and type-Il activated macrophages (bottom panels) in the presence of antigen. T cells 
were selected by gating for Thyl.2
+
 cells, then measured for CD25 (left), CD69 (center), 
and CD62L (right) expression. Figures are representative of at least three independent 
experiments. 
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activators of naïve T cells. The co-cultivation of T cells with Ca-MΦ was also able to 
induce T cell activation markers, albeit slightly less than MΦ-II. There was a slight 
decrease in the up-regulation of CD25 and CD69 and less of a down-regulation of 
CD62L (Figure 15).  Alternatively activated macrophages induced only minimal signs of 
T cell activation, which were similar to unstimulated macrophages. Thus, MΦ-II appear 
to be very efficient antigen presenting cells, and this is in stark contrast to AA-MΦ which 
were poor at inducing T cell activation.  
 
Activated macrophages drive different levels of T-cell proliferation   
To directly compare T cell activation by these three populations of macrophages, 
CD3
+
 T-cells were CFSE stained, and added to each population of macrophages 2 hours 
after stimulation in the presence of antigen. Macrophages and T cells were co-cultured 
for 96 hours and stained with PE-conjugated α-Thy 1.2.  Proliferation of Thyl.2
+
 cells 
was assessed by flow cytometry. As expected, resting macrophages given antigen alone 
were able to drive only minimal levels of T cell proliferation, as shown by minimal 
dilution of the CFSE stain (Figure 16A). AA-MΦ were equally poor at driving T cell 
proliferation (Figure 16A).  Both CA-MΦ and MΦ-II induced a robust primary T cell 
response characterized by several rounds of T cell proliferation (Figure 16A). Thus, MΦ-
II are particularly effective as APCs, inducing the rapid expression of early activation 
markers (Figure 15) supporting T cell proliferation (Figure 16).  AA-MΦ, in contrast, are 
relatively poor at inducing T cell activation markers and they fail to support the 
proliferation of naïve T cells.  Even after stimulation with LPS, IL-4 primed macrophages 
failed to support substantial amounts of T cell proliferation (Figure 16B). 














































Figure 16: Activated macrophages drive different levels of T cell proliferation. 
(A) Naïve T cells were isolated from total splenocytes from DO11.10 mice, CFSE 
stained, then co-cultured in the presence of unstimulated (top panel), alternatively 
activated (upper middle panel), classically activated (lower middle panel), or type-II 
activated macrophages (bottom panel) in the presence of 150 µg/ml OVA. CFSE profiles 
of Thy1.2
+ 
T cells were measured after 96 hours of co-culture. (B) AA-MΦ given OVA 
alone (upper panel) or OVA+LPS (10ng/ml, center panel). MΦ-II were used as antigen 




 89  
T-cell Biasing by Activated Macrophage Populations 
 We also examined secondary T cell responses to antigen and APCs.  For these 
assays, T cells were stimulated with each of the macrophage populations and antigen for 
7 days. T cells were washed and restimulated under non-biasing conditions with plate 
bound anti-CD3 for 24 hours. Cytokine levels were measured by ELISA. Although 
cytokine production from T cells activated by MΦ-II has previously been examined
91
, a 
comparison between the three cell types has not been reported. T-cells activated by Ca-
MΦ (LPS+OVA) produced relatively high levels of IFN-γ and less IL-4, whereas T-cells 
activated by MΦ-II produced relatively high levels of IL-4 and significantly reduced 
levels of IFN-γ (Figure 17A), as previously reported
91
. We measured IL-10 production 
from these T cells. MΦ-II give rise to T cells that produced high levels of IL-10 in the 
secondary response, whereas Ca-MΦ induced a population of T cells that produced only 
modest levels of IL-10, as measured by ELISA (Figure 17B). T cells biased by MΦ-II 
also had high levels of IL-10 mRNA 24 hours after restimulation (Figure 17C). These 
differences in cytokine production are not due to an overall lack of antigen presentation, 
since Ca-MΦ induced relatively high levels of IFN-γ production from T cells (Figure 
17A). AA-MΦ failed to induce IL-10 production in the secondary response, possibly due 
to the lack of significant levels of proliferation in the primary response. Flow cytometry 
and intracellular cytokine staining was used to measure cytokine production on the single 
cell level (Figure 18).  Following T cell activation by Ca-MΦ, there was only a small 
percentage of T-cells in the population that produced IL-4 (5.8%) or IL-10 (1%) (Figure 
18, left panel). There were few if any double producers. In contrast, following activation 
with MΦ-II a substantial portion of the T cell population produced IL-4 (31.6%) or IL-10  
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Figure 17: Cytokine profiles of T cells after secondary stimulation.  
T cells were co-cultured with AA-MΦ, Ca-MΦ, or MΦ-II for one week, washed, then 
restimulated with plate-bound α-CD3 (5 µg/ml). (A) T cell cytokine production 
following primary stimulation with Ca-MΦ (top) or MΦ-II (bottom), as previously 
described. (B) IL-10 from T cells restimulated for 24 hours as measured by ELISA. (C) 
QRT-PCR measuring IL-10 mRNA 24 hours after restimulation with α-CD3 after 
primary stimulation with Ca-MΦ or MΦ-II. mRNA levels are presented relative to naïve 
T-cell IL-10 mRNA. Figures are representative of at least three independent experiments. 
Error bars indicate ± SD.  


























Figure 18: Intracellular staining for IL-4 and IL-10 after secondary stimulation. 
T cells were re-stimulated for 6 hours in the presence of GolgiStop (monensin) with 
plate-bound α-CD3e after biasing and activation by Ca-MΦ (Left Panel) or MΦ-II (Right 
Panel). Cells were fixed/permeablized using the Cytofix/Cytoperm reagent and stained 
using a PE-conjugated antibody against IL-4 and a FITC-conjugated antibody against IL-
10. Quadrants are set using appropriate isotype controls. Figures are representative of at 











Conditions: Ca-MΦ                                           MΦ-II 
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The classical activation of macrophages leads to the production of a variety of 
lipid mediators, cytokines and chemokines. These mediators make classically activated 
macrophages important effector cells that can efficiently kill intracellular 
microorganisms.  These same mediators, however, make these cells potent inflammatory 
cells that can mediate autoimmune pathologies. The thorough characterization of 
classically activated macrophages has been greatly aided by the reliable generation of 
these cells in vitro, simply by priming cultured macrophages with IFN-γ and then 
stimulating them with TNF or TLR activators.  These defined in vitro studies have told us 
a great deal about the activation response and the biochemistry of the mediators produced 
during it.  Alternatively Activated macrophages (AA-MΦ) were first identified following 
the addition of IL-4 to cultures of resident macrophages.  These cells were shown to 
express higher levels of the mannose receptor
69
. Subsequent studies have identified a 
number of reliable "markers" for the AA-MΦ, including FIZZ1 and YM1/2
153,161
. Many 
of the studies to characterize the AA-MΦ were performed on macrophages isolated from 




 infections. These studies 
showed that AA-MΦ are physiologically distinct from classically activated macrophages, 
in that they up-regulate the ECM associated proteins fibronectin and βIG-H3
163
, the  
chemokine AMAC-1 (alternative macrophage associated chemokines 1)
164
, and the 
receptor for β-glucan, Dectin-1
165
. The expression of arginase by murine AA-
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macrophages restricts the availablility of L-arginine, a substrate for iNOS. This not only 
prevents NO production by these cells, but also gives them the ability to contribute to the 
formation of the extracellular matrix through the production of proline
166
. It should be 
noted that human monocytes may not respond to Th2 cytokines in the same way as 
murine bone marrow derived macrophage cells, because they fail to upregulate arginase 
activity when treated with IL-13
167
. Alternatively activated macrophages may provide 
immunity during helminth infections
168
, but they can also contribute to disease pathology 
in a murine model of experimental schistosomiasis
20
. Despite all we now know about 
these cells from disease models, a careful parallel comparison with other macrophages 
following defined in vitro activation conditions has not been performed previously.   
The type II activated macrophage (MΦ-II) remains poorly characterized, relative 
to these other macrophage populations.  The lab has previously reported on the alterations 
in cytokine production by these cells 
90,91
 and on functional properties that are distinct 
from classically activated macrophages
92
. These cells develop during some Leishmania 
infections and contribute to disease progression
56
. We show that MΦ-II lack arginase and 
are thus unable to produce urea from arginine. In this respect, they are similar to Ca-MΦ 
but markedly different from AA-MΦ. MΦ-II express high levels of co-stimulatory 
molecules and are efficient antigen presenting cells, another property that distinguishes 
them from AA-MΦ. Finally, neither MΦ-II nor Ca-MΦ expresses FIZZ1 or YM1, two 
markers for AA-MΦ. Thus, there are clear biochemical and functional distinctions 
between these two populations of macrophages. We also compared MΦ-II with Ca-MΦ 
by microarray analysis and found that there were only a limited number of transcripts that 
were different between these two populations.  
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We identified two potential "markers" for MΦ-II . We show that MΦ-II up-
regulate LIGHT (homologous to Lymphotoxins, shows inducible expression, and 
competes with herpes simplex virus glycoprotein D for HVEM/TNF-related 2).  LIGHT 
may not only be a marker for MΦ-II, but it may also bear functional activity.  LIGHT has 
been shown to costimulate T-cell responses through HVEM (TR2)
169
, which is 
ubiquitously expressed on most lymphocyte populations
170
. LIGHT can also transmit 
costimulatory signals into T-cells through interactions with the soluble receptor TR6, 
enhancing activation in response to suboptimal TCR interactions
171,172
. Thus, LIGHT 
may play a role as an additional costimulatory molecule contributing to T-cell activation 
and proliferation in response to MΦ-II.  In addition to LIGHT, Sphingosine kinase-1 may 
be another previously undescribed marker for the MΦ-II.  Sphingosine kinases catalyze 
the production of sphingosine-1 phosphate from sphingosine. Mice have two isoforms, 
SPHK1a and SPHK1b, of which it appears that only SPHK1a is appreciably expressed in 
MΦ-II. These two proteins can differ with respect to enzymatic activity, stability, and 
cellular location
156
. SPHK1 has been shown to be necessary for C5a-triggered 
intracellular Ca(2+) signals
173
. Although this does not necessarily fit our model of MΦ-II 
being anti-inflammatory macrophages, this enzyme may be an important mediator of 
calcium fluxes in these macrophages. It has also been proposed that SPHK1 may play a 
role in retaining cell viability of endotoxin stimulated macrophages
157
. We show that 
macrophages stimulated with LPS+IC, as compared to macrophages stimulated with LPS 
alone, have markedly enhanced cell survival. This may be a contribution of high SPHK1 
expression. In T cells SPHK1 controls the overproduction of the Th1-associated 
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cytokines, IL-2, TNF-α, and IFN-γ
174
. Thus, the induction of sphingosine kinase may be 
an important negative-regulator of inflammatory cytokines and chemokines in the MΦ-II. 
 In summary this side-by-side comparison of three distinct populations of activated 
macrophages has allowed us to characterize each with regard to physiology and 
functionality, and gives us the potential to develop a specific panel of markers for these 
macrophage populations. These specific "signatures" for each of the various activated 
macrophage populations may allow us to identify specific populations of macrophages 
associated with different disease states. 
 Future research should focus on several aspects of the biology of the type II 
activated macrophages. We show that naïve T-cells activated and biased by the presence 
of MΦ-II produce high levels of the Th2 associated cytokine IL-4 and IL-10. These 
biased T-cells cells should in turn be used to activate macrophages, with the hypothesis 
that MΦ-II can drive Th2 differentiation which could in turn drive alternative 
macrophage differentiation. Simple expression analysis for the various markers for 
alternative activation could be used to determine the activation status of these cells. 
Additionally, the role of SPHK1 has not fully been assessed. Although we hypothesize 
that SPHK1 may contribute to enhanced viability of MΦ-II, this may not be the case. 
Enzymatic activity should be assessed by looking at accumulation of sphingosine-1 
phosphate and comparing MΦ-II to Ca-MΦ. Furthermore, there are several inhibitors of 
SPHK available which could be added at various times to look for a role in retaining cell 
viability. Most importantly, the full potential of the microarray has not fully been 
exploited. The genes present in table 4 have not been fully assessed as potential markers 
for MΦ-II.   
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CHAPTER 4: REGULATION OF HEPARIN-BINDING EGF-LIKE 
GROWTH FACTOR BY THE TYPE II ACTIVATED 
MACROPHAGE 
 
The induction of Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-
EGF) mRNA and protein  
We previously performed microarray analyses on macrophages stimulated with LPS 
in the presence of immune complexes (IC), and compared this to macrophages stimulated 
with LPS alone. Stimulation in the presence of IC activated a specific subset of genes 
relative to those stimulated with LPS alone(
175
 and GEO dataset GDS2041, Table 3). One 
gene, Heparin-Binding Epidermal Growth Factor (HB-EGF), was found to be induced by 
an average of approximately 8-fold over macrophages stimulated with LPS alone
175
 
(Table 3). Due to the strong signal, high fold-change over LPS stimulated macrophages, 
and the potential importance of HB-EGF to macrophage biology, we decided to further 
examine the induction of HB-EGF mRNA in these cells. Macrophages stimulated with 
LPS+IC synthesized HB-EGF mRNA (Figure 19A). Macrophages stimulated with LPS 
alone also increased HB-EGF mRNA production, however this increase was relatively 
modest compared to those stimulated with LPS+IC. At the peak of mRNA induction at 
90 min, LPS+IC simulated macrophages expressed 7- to 8-fold more HB-EGF mRNA 
than cells stimulated with LPS alone, and these elevated levels were maintained for three 
hours post-stimulation (Figure 19A). Elevated HB-EGF mRNA levels were confirmed 
and visualized by conventional PCR (Figure 20A). In addition, stimulation with 
endogenous TLR4 ligand low molecular weight hyaluronic acid (LMW- HA), also a  






























Figure 19: Heparin-binding EGF-like growth factor is induced in bone-marrow 
derived macrophages in response to LPS and immune complexes (IC). 
(A) Real-time (QRT-PCR) of HB-EGF expression in bone-marrow derived macrophages 
(BMMΦ) after stimulation with LPS (10ng/ml) alone or LPS+IgG-OVA immune 
complexes (IC). QRT-PCR for HB-EGF mRNA is expressed as a fold change over 
unstimulated conditions (0’). (B) Western blot for HB-EGF in cell lysates or 
immunoprecipitated from cell culture supernatants of unstimulated (NS) macrophages or 
macrophages stimulated with LPS (10ng/ml) or LPS+IC for 16h. Figures are 
representative of at least three independent experiments.  
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Figure 20: Immune complexes enhance TLR agonist induced HB-EGF expression. 
(A) RT-PCR measuring HB-EGF mRNA from macrophages stimulated with LPS 
(10ng/ml) or LPS/IC. (B) RT -PCR measuring HB-EGF mRNA from macrophages 
stimulated with hyaluronic acid (HA, 10µg/ml) or HA/IC. RT-PCR for GAPDH is 
present as a loading control. Figures are representative of at least three independent 
experiments.  
 99  
TLR4 ligand, yielded similar results when combined with immune complexes (Figure 
20B). 
 Like other members of Epidermal Growth Factor (EGF) family, HB-EGF is 
synthesized as a membrane associated precursor (proHB-EGF) that is subsequently 
cleaved, yielding a soluble and active growth factor
176
. To determine whether HB-EGF is 
secreted or retained on the cell surface, macrophages were stimulated for 24 hours with 
LPS+IC, then cell culture supernatants and cell lysates were analyzed by 
immunoprecipitation using a polyclonal antibody specific for HB-EGF. 
Immunoprecipitated HB-EGF was subject to SDS-PAGE. A band corresponding to 
processed sHB-EGF, with a molecular weight of approximately 20kd, was detected in 
culture supernatants of macrophages stimulated with LPS+IC at 24 hours (Figure 19B). 
Macrophages stimulated with LPS alone did not secrete sHB-EGF.  Furthermore, proHB-
EGF was not detected in cell lysates from any of the cells. Thus, HB-EGF is synthesized 
by macrophages stimulated with LPS+IC and is rapidly cleaved to yield the soluble 
secreted form.  
 
The induction of HB-EGF is due to increased transcription and not to changes in mRNA 
stability 
 Other groups have reported that high levels of HB-EGF mRNA are due to 
changes in mRNA stability. Sorensen et al. reported that the 3’UTR of HB-EGF contains 
6 AU rich elements (ARE), which are essential for full induction of HB-EGF
137
. To 
determine whether the high levels of HB-EGF mRNA were due to changes in mRNA 
stability we performed an mRNA stability assay.  First, macrophages were pre-treated 
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with increasing concentrations of the transcriptional inhibitor actinomycin D, then 
stimulated with LPS+IC. HB-EGF mRNA was measured by QRT-PCR (Figure 21A). 
With increasing concentrations of actinomycin D, HB-EGF mRNA levels declined to 
basal levels, indicating that new transcription was essential for HB-EGF induction. 
Maximal inhibition was achieved at 0.5-1 µg/ml actinomycin D.  To analyze mRNA 
stability, macrophages were stimulated with LPS or LPS+IC for two hours, and then 0.5 
µg/ml actinomycin D was added.  HB-EGF mRNA levels were measured by QRT-PCR 
for 2 hours thereafter (Figure 21B). Although macrophages stimulated with LPS+IC had 
approximately 5 fold greater levels of HB-EGF mRNA than LPS stimulation alone, the 
rate at which the mRNA was degraded was similar to that of macrophages stimulated 
with LPS alone. Therefore, the high degree of HB-EGF mRNA induction in macrophages 
stimulated with LPS+IC relative to cells stimulated with LPS alone was not due to 
alterations in mRNA stability. 
 
The role of MAPK and Syk activation in HB-EGF and IL-10 induction 
 The lab has previously demonstrated that IL-10 was induced by stimulation of 
macrophages with TLR agonists in combination with IC, and that this induction was 
dependant upon the activation of the MAPKs ERK1/2 and p38
106
. In MΦ-II, HB-EGF 
follows a similar pattern of induction as IL-10, in that i) it is induced very early after 
activation, and ii) LPS alone induces only modest induction, whereas stimulation (with 
LPS) in the presence of immune complexes induces robust induction. We therefore 
wished to investigate whether ERK and p38 were also involved in the induction of HB-
EGF. Macrophages were pretreated for one hour with increasing concentrations of the  
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Figure 21: The induction of HB-EGF depends on new transcription and not on 
alterations in mRNA stability. 
(A) BMMΦ were pretreated for 1h with increasing concentrations of actinomycin D (0-
2.0µg/ml) then stimulated with LPS(10ng/ml)+IC for 2h. Relative HB-EGF mRNA was 
measured by QRT-PCR and presented as a percentage of HB-EGF mRNA present in 
macrophages stimulated in the presence of the vehicle control (0µg/ml). (B) mRNA 
stability was examined in which BMMΦ were stimulated for 2h with LPS(10ng/ml) or 
LPS+IC before the addition of 0.5µg/ml of actinomycin D. Relative levels of HB-EGF 
mRNA were measured by QRT-PCR for 2h after stimulation. Error bars indicate ± 
standard deviation. Figures are representative of at least three independent experiments. 
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MEK1,2 inhibitor (U0126, 0-4.0µM) before
 
stimulation in the presence of immune 
complexes. HB-EGF mRNA was measured by QRT-PCR 2 hours after activation (Figure 
22A, left) and IL-10 cytokine levels were measured by ELISA after 8 hours (Figure 22A, 
right). As previously reported, increasing concentrations of U0126 inhibited the super-
induction of IL-10 (Figure 22A, right).  HB-EGF mRNA production followed a similar 
pattern of inhibition in response to comparable concentrations of U0126 (Figure 22A, 
left).  Similar results were obtained when the p38 MAPK was inhibited by SB203580.  
Both IL-10 (Figure 22B, right) and HB-EGF (Figure 22B, left) were inhibited at 
comparable inhibitor concentrations.  As a control, the JNK inhibitor II only minimally 
decreased IL-10 and HB-EGF production when used at concentrations sufficient to 
significantly inhibit the secretion of TNF-α (Figure 22C). 
 We next investigated the necessity for Syk in HB-EGF induction. This signaling 
molecule has been shown by us to be necessary for full activation of ERK by immune 
complexes and the production of IL-10 by immune complexes
117
. Inhibition of FcγR 
signaling was achieved by treating BMMΦ with increasing concentrations of the Syk 
inhibitor 3-(1-Methyl-1H-indol-3-yl-methylene)-2-oxo-2,3-dihydro-1H-indole-5-
sulfonamide before activation with LPS+IC. HB-EGF was measured by QRT-PCR 2h 
after activation. IL-10 was measured by ELISA from cell culture supernatants 8h after 
activation. Treatment of macrophages with increasing concentrations of the Syk inhibitor 
greatly diminished their production of both HB-EGF (Figure 23A) and IL-10 (Figure 
23B), indicating that both IL-10 and HB-EGF superinduction by immune complexes 
requires Syk mediated FcγR signaling. Thus, the MAPKs ERK1/2 and p38 are required 
for the optimal induction of both HB-EGF and IL-10 in MΦ-II.   
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Figure 22: Immune complex mediated induction of HB-EGF requires the activity of 
ERK1/2 and p38. 
BMMΦ were pretreated with increasing concentrations of the inhibitors of the ERK1/2 
pathway (A, U0126 0-4.0µM), p38 (B, SB203580 0-4.0µM), JNK(C, JNK Inhibitor II 0-
4.0µM). BMMΦ were then stimulated with LPS (10ng/ml)+IC for 2h. HB-EGF mRNA 
was measured by QRT-PCR and expressed relative to vehicle controls (A-D, left panels). 
IL-10 protein was measured by ELISA after 8h of stimulation and expressed as a 
percentage of protein relative to vehicle controls (A-D, right panels). Figures are 
representative of at least three independent experiments. Error bars indicate ± standard 
deviation. Asterisk indicates (*)p<0.05 and (**p<0.01) as compared to vehicle alone 
control.  
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Figure 23: Immune complex mediated induction of HB-EGF requires Syk activity. 
BMMΦ were pretreated with increasing concentrations of the inhibitor of Syk (Syk 
Inhibitor 0-4.0µM). BMMΦ were then stimulated with LPS (10ng/ml)+IC for 2h. (A) 
HB-EGF mRNA was measured by QRT-PCR and expressed relative to vehicle controls. 
(B) IL-10 protein was measured by ELISA after 8h of stimulation and expressed as a 
percentage of protein relative to vehicle controls. Figures are representative of at least 
three independent experiments. Error bars indicate ± standard deviation. ** indicates 
p<0.01 as compared to vehicle alone control. 
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The induction of HB-EGF mRNA is not dependant upon IL-10 
 The sensitivity of HB-EGF induction to inhibition of ERK and p38 suggested that 
HB-EGF was induced by mechanisms that are similar to those of IL-10.  An alternative 
interpretation would be that IL-10 is required for HB-EGF induction.  We considered this 
to be unlikely due to rapid induction of HB-EGF mRNA following stimulation, but to 
directly address this possibility HB-EGF induction in macrophages deficient in IL-10 was 
examined.  Both wild-type and IL-10
-/-
 macrophages produced comparable levels of HB-
EGF mRNA in response to stimulation by LPS+IC (Figure 24A).     
 Additionally, to block the production of IL-10, macrophages were pretreated with 
increasing concentrations of the translation inhibitor, cycloheximide. As expected, 
stimulation of macrophages with LPS+IC led to high levels of IL-10 protein, which were 
diminished to undetectable levels with increasing concentrations of cycloheximide (0.00 
to 0.50µg/ml, Figure 24B, solid). Parallel to this, HB-EGF mRNA was measured two 
hours after stimulation with LPS+IC by QRT-PCR. Increasing concentrations of 
cycloheximide failed to significantly diminish HB-EGF mRNA (Figure 24B, bars), while 
blocking the production of IL-10 protein. Thus, the production of HB-EGF by MΦ-II 
does not depend on IL-10 production. 
  
5’ RNA Ligase Mediated Rapid Amplification of cDNA Ends (5’-RLM-RACE) for HB-
EGF 
 In order to be sure of the position of transcription factors along the HB-EGF  
promoter relative to the transcriptional start site, 5’ rapid amplification of cDNA ends 
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Figure 24: Immune complex-mediated induction of HB-EGF mRNA does not 
require IL-10 protein synthesis. 
(A) BMMΦ from wild-type or IL-10
-/-
 mice were stimulated with LPS (10ng/ml) or 
LPS+IC and HB-EGF mRNA was measured at 2h after stimulation. (B) BMMΦ were 
pretreated for 1h with increasing concentrations of actinomycin D (0-0.5µg/ml) then 
stimulated with LPS+IC. IL-10 protein was measured by ELISA 8h after stimulation 
(line) and HB-EGF mRNA was measured by QRT-PCR after stimulation for 2h (bar). 
mRNA levels are presented relative to unstimulated controls. Error bars indicate ± 
standard deviation. Figures are representative of at least three independent experiments. 
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was performed. The transcriptional start site was previously determined for 
differentiating myotubes
142
, but not for activated macrophages. The nested PCR reaction 
produced a band of the expected size of approximately 450bp. EcoRI digestion of TOPO 
TA clones from the nested PCR reaction revealed clones of three different sizes (Figure 
25). Of the 20 digested plasmids, 8 were self ligations, 8 contained the expected product 
size of approximately 450bp, one contained a product of approximately 350bp, and 3 
contained a product of approximately 250bp. All three of these plasmids were sequenced. 
The major clone contained the previously reported sequence. The second clone contained 
a product missing approximately the first 120bp of the first exon and is likely to simply 
be a partially degraded mRNA. The third clone was missing the central 233bp of the first 
exon, which contains the translational start site for HB-EGF. Although not confirmed, 
this most likely represents a nonsense and therefore non-functional mRNA. Despite the 
presence of the two minor clones, these results essentially confirm the previously 
reported transcriptional start site for HB-EGF (Figure 25).  
 
Sp1 transcription factor binds to the HB-EGF promoter in situ and in vitro 
 The robust induction of HB-EGF mRNA in macrophages stimulated with LPS+IC 
prompted us to determine which transcription factors may play a role in HB-EGF 
transcription. Preliminary promoter analysis using Transfac (default 85% cutoff; 
http://www.gene-regulation.com/pub/databases.html 
177
) revealed 3 potential Sp1 binding 
sites within the first 2kb of the HB-EGF promoter (Table 4). In order to determine the 
binding of Sp1 to the HB-EGF promoter in situ in
 
live cells, a ChIP assay was performed.  
BMMΦ were stimulated
 
with LPS+IC, and then processed for ChIP analysis
 
using an 



































Figure 25: 5’-RLM-RACE for HB-EGF. 
The RACE adaptor is ligated to the 5’ end of full-length mRNA, reverse transcribed, 
followed by a nested PCR using external and internal RACE adaptor and gene specific 
primers. (A) Nested PCR using Fast Start High Fidelity PCR System (1) and Platinum 
PCR Supermix High Fidelity (2). Nested reactions are labeled 1-2 and 2-2. (B) TA 
cloning of product from nested PCR excised using EcoRV. (C) Sequences of fragments 
from (B). Blue text denotes RACE adaptor, green texts denotes internal gene specific 
reverse primer, red underlined text denotes translation start site, red text denotes where 
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anti-Sp1 antibody. An analysis of the the HB-EGF promoter (-2000/+292) using 13 
primer pairs (Figure 26A) revealed Sp1 binding to three regions of the Sp1 promoter 
(amplicons 3,8, and 11), each of which contain a predicted Sp1 binding site. Table 4 
contains these primers pairs and a schematic of these predicted Sp1 binding sites. A 
kinetic analysis of these regions revealed a rapid, although transient, binding of Sp1 to 
the HB-EGF promoter which peaked at approximately 45 minutes (Figure 26B, 
amplicons 3, 8, 11). As a control, an upstream
 
region (-2000/-1849) of the HB-EGF 
promoter
 
was also analyzed. It failed to efficiently recruit Sp1 (Figure 26B, amplicon 13). 
 EMSAs were performed in order to determine if the predicted promoter elements 
could be directly bound by Sp1. For these assays, the macrophage-like RAW264.7 cell 
line was used.  These cells respond similarly to primary macrophages in their HB-EGF 
induction, following stimulation with LPS or LPS+IC (see Figure 27A). Nuclear proteins 
were mixed with a consensus probe or with a probe corresponding to a potential Sp1 
binding site within -1566/-1548 of the HB-EGF promoter (relative to the transcriptional 
start site).  By EMSA, Sp1 bound to both probes following the addition of nuclear 
extracts from either stimulated or resting cells (Figure 27A).  In Figure 27, the asterisks 
indicate bands corresponding to Sp1 bound to these probes. Free probe without nuclear 
extracts (FP) did not reveal this band.  Despite the dramatic differences in HB-EGF 
production following stimulation, there were no detectable differences in the amount of 
Sp1 binding when extracts from unstimulated RAW264.7 cells, or cells stimulated with 
LPS or LPS+IC were added.  All of these extracts contained Sp1 that was competent to  
bind to these probes (Figure 27A). Two additional probes corresponding to the other Sp1 
binding sites were also confirmed to have Sp1 binding activity in vitro (Figure 27B-C). 






































Table 4: Schematic diagram and table of primers used for analysis of the HB-EGF 
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-2000bp/ +291bp (HB-EGF)




























































Figure 26: Sp1 is recruited to the HB-EGF promoter in situ by BMMΦ after 
stimulation with LPS+IC. 
(A) BMMΦ were stimulated with immune complexes (IC) and 10 ng/ml LPS (IC/LPS) for 0 and 
45 minutes. Cross-linked chromatin fragments were immunoprecipitated with anti-Sp1 antibody. 
Immunoprecipitated DNA was purified and examined for the presence of HB-EGF promoter 
sequences corresponding to each of the 13 amplicons with the corresponding primers present in 
table 4 as measured by QRT-PCR. The data were normalized to inputs at each time point and 
plotted graphically as fold changes relative to the data at 0 min. (B) BMMΦ were stimulated with 
immune complexes (IC) and 10 ng/ml LPS (IC/LPS) for 0, 15, 30, 45, 60 and 90 min and 
processed for ChIP as in (A). DNA was purified and examined for the presence of HB-EGF 
promoter sequences corresponding to amplicons 3, 8, 11, and 13 by QRT-PCR. Figures are 
representative of at least two independent experiments. 



































Figure 27: Sp1 binds potential Sp1 sites of the HB-EGF promoter in vitro. 
(A) 
32
P labeled double-stranded oligomers corresponding to a consensus Sp1 binding 
sequence or the -1566/-1548 of the HB-EGF promoter were incubated on ice for 1h with 
nuclear extracts from unstimulated (NS), LPS or LPS+IC stimulated (45’) RAW264.7 
cells. FP=Free Probe. Labeled probes corresponding to the -86/-48 (B), -1015/-996 (C), 
and the -1566/-1548 (D) potential Sp1 sites of the HB-EGF promoter were incubated 
with nuclear extracts from RAW264.7 cells stimulated with LPS+IC for 45’. Binding was 
competed with increasing concentrations (10×-50×) of cold unlabeled probe or consensus 
cold probe. DNA-Sp1 protein complexes were supershifted by incubating nuclear 
extracts with 1 or 3µg of antibody against Sp1 or Histone H3 for 30’ on ice prior to 
incubation with labeled probe (B-D). *Indicates Sp1-DNA complexes. Arrowheads 
indicate supershifted Sp1-DNA complexes. 
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This binding was competed for by increasing
 
molar ratios of a cold probe (10x-50x) 
corresponding to this site or to a cold consensus probe. In all cases (Figure 27B-D), the 
addition of an antibody against Sp1 (1µg or 3µg) prior to the addition of labeled probe 
resulted in a supershift (arrow). Thus, the EMSA confirms that all three sites identified by 
ChIP can bind to Sp1 in vitro. However, there was a clear and important distinction 
between the results obtained with ChIP and with EMSA.  Resting cells did not exhibit 
significant Sp1 ChIP activity at the HB-EGF promoter (Figure 26B, Time 0), whereas by 
EMSA their nuclei clearly contained Sp1 that was fully competent to bind DNA, and this 
binding was comparable to that of stimulated cells.  
 
Activity of an HB-EGF Reporter Construct in Response to stimulation  
 In order to address which promoter elements were necessary for the transcription 
of HB-EGF, reporter plasmids containing portions of the HB-EGF promoter were 
transfected into RAW264.7 cells. The lab and others have previously used this cell line to 
study the regulation of IL-10
94,101
.  By RT-PCR, RAW264.7 cells respond similarly to 
primary bone-marrow derived macrophages in the induction of HB-EGF mRNA. Similar 
to primary macrophages, stimulation with LPS alone resulted in modest levels of HB-
EGF mRNA, which were dramatically increased when combined with immune 
complexes (Figure 28A). Three HB-EGF promoter reporter plasmids were constructed, 
including the first ~2700 bases of the HB-EGF promoter (-2704/+330), as well as two 
truncations (-1238/+330 and -557/+330) (Figure 28B). The -2704/+330 plasmid contains 
three potential Sp1 binding sites, while the -1230/+330 and the -557/+330 plasmid 
contained two and one binding sites, respectively. Luciferase activity was unchanged  
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Figure 28: Luciferase activity of RAW264.7 cells transfected with wild-type and 
mutant HB-EGF reporter vectors after stimulation with LPS or LPS+IC. 
(A) RAW264.7 cells were stimulated with LPS or LPS+IC for 1, 2, or 3h or left 
unstimulated (NS). HB-EGF and GAPDH mRNA were measured by RT-PCR. GAPDH 
is present as a loading control. (B) Schematic illustration of luciferase reporter constructs 
of the HB-EGF promoter. pGL4.19 luciferase reporter constructs containing -2704/+330, 
-1238/+330, -557/+330 or none of the HB-EGF promoter were transfected into 
RAW264.7 cells overnight then stimulated with LPS(1 or 10ng/ml) or LPS+IC for 8 
hours. Each sample was measured for firefly luciferase activity and normalized to renilla 
luciferase activity (transfected at a ratio of 40:1). Values are represented as fold changes 
relative to unstimulated cells transfected with the empty vector. Figures are representative 
of at least three independent experiments. Error bars indicate ± standard deviation of experiments 
performed in triplicate.  
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following stimulation of RAW cells transfected with empty pGL4.19 vector (Figure 
28B). Transfection of the -2704/+330 plasmid resulted in only minor increases over the 
level of activity of the empty vector. However, truncation of the promoter (to -1238) 
strongly enhanced the activity of the promoter upon stimulation (Figure 28B). The most 
severely truncated HB-EGF promoter analyzed (-557) displayed similarly increased 
levels of luciferase activity upon stimulation (Figure 28B). Importantly, both of these 
vectors (-1238 and -557) responded equally well to stimulation with LPS or LPS+IC. 
Thus, luciferase activity did not accurately reflect HB-EGF mRNA induction, since the 
combination of LPS+IC did not result in a super-induction of luciferase activity.   
 Since both the -1230/+330 and the -557/+330 promoter plasmids responded 
similarly to stimulation with LPS+IC, we investigated whether the Sp1 binding site 
located within -83/-54 was required for the response to LPS+IC. This region actually 
contains 3 potential Sp1 binding sites directly adjacent to each other (Figure 29A). In 
order to assess the importance of this region, we used site-directed mutagenesis to modify 
two nucleotides of the conserved core binding site of GGGCGG to GGTAGG (Figure 
30A) at each of these sites. Transfection of the -557/+330 led to a constitutive 
enhancement in luciferase activity that was further enhanced upon stimulation with 
LPS+IC for 8h (Figure 29B). However, both the constitutive activity as well as the 
induced activity were nearly completely nullified by mutating these sites (Figure 29B). 
Thus, this site binds Sp1, and this binding is required for the activity of the HB-EGF 
promoter.  
 
Enhanced HB-EGF Promoter Accessibility in Response to LPS+IC 
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-83/-54 WT-Sp1   AAGGGGGCGGTGCCGGGCGGGGCGGGGCTC
-83/-54 MT-Sp1   AAGGGGTAGGTGCCGGTAGGGTAGGGGCTC 
* * *





































Figure 29: Sp1 site located at -83/-54 is required for HB-EGF promoter activity. 
(A) Schematic of the mutations made in the Sp1 site contained in the -557/+330 vector. 
The central GC of the three conserved core GGGCGG sequences was mutated to TA by 
site-directed mutagenesis. (B) RAW264.7 cells were transfected with the empty vector or 
the -557/+330 HB-EGF reporter vector containing the wild-type or mutant Sp1 binding 
site overnight then stimulated with LPS(10ng/ml)+IC for 8h. Samples were analyzed as 
described in B, and represented as fold changes from unstimulated cells transfected with 
the empty vector. Error bars indicate ± standard deviation. Asterisk indicates a p-value of 
<0.001 as comparing media or LPS+IC conditions from wild-type to mutant -557/+330 
transfected cells. Figures are representative of at least three independent experiments. 
Error bars indicate ± standard deviation of experiments performed in triplicate.  
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 To explain the seemingly discordant data concerning the constitutive DNA 
binding ability of Sp1 by EMSA, the increase in the recruitment to the HB-EGF locus by 
ChIP, as well as the difference between luciferase activity and mRNA production, we 
decided to determine whether HB-EGF was regulated, at least in part, at the level of 
chromatin and locus accessibility. We examined the
 
sensitivity of DNA to cleavage by 
DNase before and after stimulation of macrophages with LPS+IC (Figure 30). Chromatin 
sensitivity to DNase
 
was measured at amplicons 3, 8, and 11 and compared with a region 
of the TdT gene, which is not expressed in macrophages
178
. At 0’ (unstimulated cells), all 
of these regions were relatively
 
resistant to DNase cleavage. Within minutes of 
stimulation, all three regions studied showed a dramatic increase in accessibility to the 
DNase enzyme. Although each region showed slightly different kinetics, the extent of the 
accessibility increase was comparable in all three regions (Figure 30). This was not the 
case for the TdT gene, which showed essentially no changes in accessibility over this 
period of observation (Figure 30). These data suggest that although Sp1 is constitutively 
found in the nucleus in a form that is able to bind to its cognate sequences, in 
unstimulated cells this binding does not occur. Changes in HB-EGF promoter 
accessibility allow for the association of Sp1 to the HB-EGF promoter following 
stimulation.    
  
Requirement of ERK activity for efficient Sp1 recruitment and promoter accessibility 
Our previous observations indicated that ERK activity is required for efficient 
recruitment of Sp1 to the IL-10 promoter
105
 due to ERK dependent phosphorylation of 
histone H3, which results in enhanced promoter accessibility. In order to determine   
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Figure 30: Changes in DNase I accessibility at the HB-EGF promoter. 
BMMΦ were stimulated with LPS+IC for 0, 15, 30 60, or 120 minutes then fixed with 
formaldehyde. Nuclei were isolated and treated with DNase for 1h on ice. DNA was then 
purified and subject to QRT-PCR. Data are presented as a percentage of DNase 
accessibility to amplicons 3 (A), 8 (B) and 11 (C) as normalized to undigested DNA then 
to unstimulated control. The lymphocyte specific TdT gene is present as a negative 
control for changes in DNase sensitivity. Figures are representative of at least three 
independent experiments.  
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whether ERK activity was required for efficient Sp1 recruitment to the HB-EGF 
promoter, macrophages were pretreated with the ERK inhibitor U0126 and Sp1 
recruitment to the HB-EGF promoter was measured by ChIP (Figure 31). Similar to the 
observations made in figure 5, stimulation of macrophages with LPS+IC resulted in a 
strong recruitment of Sp1 to all three regions of the HB-EGF promoter at 45’ (amplicons 
3, 8, and 13).  Blocking the ERK pathway with U0126 completely diminished Sp1 
binding at all three of these sites (Figure 31).  
 Blocking the ERK pathway also prevented stimulation-dependent increases in 
DNA accessibility at the HB-EGF promoter. Similar to figure 30, when macrophages 
were treated with LPS+IC, the HB-EGF promoter became more accessible to DNase 
activity at amplicons 3 (Figure 32A), 8 (32B), and 11 (32C). Inhibition of the ERK 
pathway with U0126, however, greatly diminished the stimulus-dependent increase in 
accessibility at the HB-EGF promoter (Figure 32A-C). Thus, both Sp1 association and 
DNase accessibility were dependent on the activation of ERK.   
    
Induction of HB-EGF by various IL-10 promoting stimuli are ERK dependent 
 We wished to determine whether IL-10 and HB-EGF were coordinately regulated 
in macrophages that were induced to over-produce IL-10 by stimuli other than immune 
complexes.  Macrophages were incubated with prostaglandin E(2), dibutyryl cAMP, or 
4T1 tumor cell culture supernatants alone or in combination with LPS. Stimulation of 
macrophages with LPS in the presence of immune complexes (Figure 34A) prostaglandin 
E(2) (Figure 34B), dibutyryl cAMP (Figure 34C),or 4T1 culture supernatants (Figure 
34D) enhanced the production of both IL-10 (left panels) and HB-EGF (right panels) 










































Figure 31: ERK dependent association of Sp1 with the HB-EGF promoter.  
BMMΦ were treated with vehicle alone or 5µM U0126 for 1h, then left unstimulated 
(Medium) or stimulated with LPS(10ng/ml)+IC for 45 minutes. Cells were then fixed and 
processed for Sp1 ChIP as described in figure 26. Sp1 association is expressed as fold 
enrichment from unstimulated vehicle control for amplicons 3, 8, and 13, each of which 
contain Sp1 binding sites. Figures are representative of at least two independent 
experiments. 
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Amplicon 8
LPS/IC (Minutes)



































































Figure 32: Erk dependent accessibility to the HB-EGF promoter. 
BMMΦ were treated with vehicle alone or 5µM U0126 for 1h, then left unstimulated (0’) 
or stimulated with LPS(10ng/ml)+IC for 15’, 30’, 60’, or 120’. Cells were then fixed and 
processed for DNase accessibility as described for figure 30. DNase accessibility is 
presented as a percentage of digested DNA as normalized to unstimulated and undigested 
controls for amplicons 3 (A), 8 (B), and 11 (C). Figures are representative of at least two 
independent experiments. 
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Figure 33: LPS induced IL-10 production is enhanced by a number of stimuli. 
Macrophages were stimulated with LPS with increasing concentrations of Prostaglandin 
E(2) (PGE-2, A), 4T1 culture supernantants (4T1%, B), and dibutyryl-cAMP (dB-cAMP, 
C). Macrophage culture supernantants were collected after 8 hours and the concentration 
of IL-10 determined by ELISA. Error bars indicate ± standard deviation of experiments 
performed in triplicate. 
 123  
mRNA, as measured by real-time PCR. None of these three stimuli when used alone 
induced either IL-10 or HB-EGF (solid line).  It was only when they were combined with 
a stimuli such as LPS (dashed lines) that the dramatic induction was observed. We next 
examined whether ERK activity was required for the enhanced production of HB-EGF in 
response to PGE-2, dibutyryl cAMP, or 4T1 culture supernatants. In the presence of 
U0126 there was a dramatic inhibition of HB-EGF mRNA induction (Figure 35) 
regardless of the stimulation conditions. Thus, both IL-10 and HB-EGF are induced by a 
variety of stimuli and in all cases this induction depends on the activation of ERK. 
 
HB-EGF and Cytokine Levels Expressed by Tumor Associated Macrophages (TAMs) 
 It has previously been observed that tumor associated macrophages express 
elevated levels of IL-10 both constitutively and after stimulation
144,179
. As we have 
established that there appears to be a mechanism of coordinate regulation between IL-10 
and HB-EGF (Figure 34), we wished to investigate if whether tumor associated 





 double positive cells were sorted from adherent cells isolated 
from homogenized 15-20mm B16 melanomas. Cells were then stimulated with LPS for 
90’ or left unstimulated. HB-EGF (Figure 36A), IL-10 (36B), and TNF-α (36C) levels 
were assessed by QRT-PCR and compared to mRNA levels from peritoneal macrophages 
of age-matched controls or tumor-bearing mice. TAMs expressed elevated levels of IL-10 
as well as elevated levels of HB-EGF, with or without stimulation with LPS. TAMs were 
devoid of TNF-α, even after stimulation with LPS (Figure 37C).   
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Figure 34: Conditions which promote IL-10 also promote HB-EGF.  
BMMΦ were stimulated with immune complexes (A, IC), 10
-8
M prostaglandin E2 (B, 
PGE-2), 27%  4T1 culture supernatants (C, 4T1), or 100µM dibutyrl cAMP (D, dB-
cAMP) in the presence or absence of LPS(10ng/ml). IL-10 (left) and HB-EGF (right) 
mRNA was measured at 0’, 30’, 60’, 90’, 120’, 150’ and 180’ by QRT-PCR and 
expressed as relative to the maximum level of HB-EGF mRNA during the stimulation 
conditions. Figures are representative of at least three independent experiments. 
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Figure 35: ERK dependent regulation of HB-EGF in response to multiple 
stimulation conditions. 
BMMΦ were pretreated for 1 hour with 5µM U0126 or vehicle alone, then stimulated 
with LPS+IC (A), LPS+PGE-2 (B), 4T1 culture supernatants (C) or LPS+dB-cAMP (D) 
for 60’, 90’, or 120’, as in figure 34. HB-EGF mRNA was measured by QRT-PCR and 
expressed relative to the maximum level of HB-EGF mRNA during the stimulation 
conditions. Figures are representative of at least three independent experiments. Asterisk 
indicates p-values <0.01. 
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Discussion 
 We have identified the production of heparin-binding EGF-like growth factor and 
describe its regulation in MΦ-II. HB-EGF is a growth factor involved in a number of 
both physiological and pathological conditions
119
. We show that there are many 
similarities between IL-10 and HB-EGF production, suggesting a common mechanism of 
gene expression. For the induction of both HB-EGF and IL-10, two of the three major 
MAPKs, p38 and ERK, are required. Blocking either of them prevents the transcription 
of both genes.   
 ERK activation results in increased accessibility of the HB-EGF promoter to the 
transcription factor Sp1, which binds to the HB-EGF promoter. This conclusion was 
reached after studies to analyze the binding of Sp1 to the HB-EGF promoter yielded 
dramatically different results, depending on the assays that were employed. The EMSA 
assays indicated that Sp1 is resident in the nucleus of unstimulated cells, and that it could 
constitutively bind to elements in the HB-EGF promoter in the absence of stimulation.  
This constitutive binding to unstimulated cells, however, was not observed by ChIP 
analysis. A potential explanation for these differences lies in the increased accessibility of 
the HB-EGF promoter to transcription factors following stimulation. Increased 
accessibility would also explain the discordant luciferase data in which LPS alone 
induced as much luciferase as did LPS+IC. Regulation at the level of chromatin 
accessibility would not be obvious during EMSA or luciferase assays, where naked DNA 
was used as the probe or readout. This increased accessibility of the HB-EGF promoter 
following stimulation was confirmed by DNase accessibility assays.  Following 
stimulation the HB-EGF promoter became more accessible to DNase cleavage, whereas  












































































Figure 36: HB-EGF and cytokine mRNA levels from tumor associated 
macrophages. 





 cells (TAM) from melanomas were left unstimulated or 
stimulated with LPS for 90’. QRT-PCR was performed to assess message levels for HB-
EGF, IL-10, and TNF-α. Values are relative to unstimulated macrophages from age-
matched controls.  
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the accessibility of a control gene that was not transcribed in macrophages was unaltered. 
This increased accessibility did not occur when ERK was inhibited.  Thus, an important 
component of the regulation of HB-EGF gene expression involves alterations in promoter 
accessibility, and ERK activation is involved in these alterations.    
By EMSA and ChIP assays, we show that Sp1 can bind to three positions along the 
HB-EGF promoter. Luciferase reporter assays were performed to determine which site 
was most closely associated with transcriptional activation. The binding of Sp1 to the 3'-
most site, located adjacent to the transcriptional start site, appeared to be required for the 
activity of the HB-EGF promoter. This site was sufficient to induce maximal luciferase 
activity.  Surprisingly, an analysis of an extended promoter, including the 5'-most site, 
not only failed to contribute to transcription but substantially diminished luciferase 
activity. The logical interpretation of these results is that a repressor element was located 
within this site. 
We examined three other conditions in which the production of IL-10 was induced 
and demonstrate that HB-EGF production was similarly regulated in an ERK dependant 
fashion. Prostaglandin E(2) (PGE-2) has been previously shown to enhance the 
endotoxin-driven production IL-10 from macrophages and monocytes
180
. We show that 
HB-EGF production is also enhanced under these conditions. Similar to what the lab has 
observed for immune complexes, PGE-2 alone induced no HB-EGF but rather 
reprogrammed macrophages to produce HB-EGF in response to stimulation with LPS 
(Figure 34). The same observations were made with supernatants from the mammary 
tumor cell line 4T1, and stimulation in the presence of dibutyryl cAMP. In all cases, HB-
EGF induction required co-stimulation with LPS and was dramatically inhibited by the 
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addition of the MEK1/2 inhibitor, U0126. Thus, the activation of ERK in macrophages 
results in a phenotype that is quite distinct from classically activated macrophages. ERK 
activation results in macrophages that are not only immunosuppressive though the 
production of IL-10, but may also contribute to angiogenesis via HB-EGF. 
 Tumor-associated macrophages have been linked enhanced tumor survival and 
progression through a number of mechanisms. This includes immunosuppression via IL-
10
179
 and angiogenesis through a number of mechanisms
145
. Tumor associated 
macrophages are not only a rich source of IL-10, but are also thought to produce a 
number of tumor promoting growth factors
145
. Elevated expression of HB-EGF has been 
found in many human tumors, and high levels have been found to correlate with poor 
prognosis
133
. In vitro and in vivo studies indicate that the expression of HB-EGF in the 
developing tumor microenvironment can contribute to angiogenesis, and thus to 
metastasis
130
. We propose that the coexpression of IL-10 and HB-EGF by macrophages 
may be a mechanism to explain this. Conditions common in the tumor microenvironment, 
such as the secretion of PGE-2 by tumor cells, appear to prime macrophages to produce 
both IL-10 and HB-EGF. Importantly, we show that both IL-10 and HB-EGF are 
dependent on the activation of ERK. These findings suggest that the inhibition of ERK 
may prevent both the immunosuppressive and the angiogenic activities of these 
macrophages.  
 Future research should focus on the production of IL-10 and HB-EGF by tumor-
associated macrophages and the specificity of the ERK-dependant enhancement of their 
production. We have investigated the expression of IL-10, HB-EGF, and TNF-α by 
tumor associated macrophages of the B16 melanoma model. We show a constitutive 
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enhancement in IL-10 and HB-EGF expression as compared to unstimulated 
macrophages from control peritoneal cells. Their expression remains unchanged by 
stimulation with LPS, unlike control cells. The constitutive enhancement of IL-10 
expression by tumor associated macrophages has previously been reported. However, 
unlike what we have seen, stimulation with LPS leads to a marked up-regulation of IL-10 
as compared to control cells. Therefore, the tumor microenvironment appears to prime 
these cells produce IL-10 even in response to an inflammatory stimulus. Therefore, future 
research should study an established model in which the expression of IL-10 has 
previously been investigated. Additionally, procedures used to enrich macrophages from 
tumors need to be revisited. The procedures used were most likely were not ideal for 
retaining the viability of macrophages and thus reproducible responsiveness to 
stimulation.  
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CHAPTER 5: ROLE OF THE MITOGEN AND STRESS 
ACTIVATED PROTEIN KINASES (MSKS) AND 
PHOSPHOINOSITIDE 3-KINASE IN THE REGULATION OF IL-10 
 
Stimulation of Macrophages Modulates the Kinase Activity of the MSKs 
 In order to determine the potential role of the MSKs in the regulation of IL-10, we 
first wished to determine if the MSKs were activated during stimulation conditions that 
promoted IL-10. As previously observed, the IL-10 promoter is phophorylated at histone 
H3 at serine 10 when macrophages are stimulated with immune complexes alone or in 
combination with LPS
106
. Therefore, we wished to determine if the MSKs were activated 
under these conditions. In order to address this, an immunoprecipitation kinase assay was 
performed. Macrophages were left unstimulated or stimulated with immune complexes 
(IC) alone or the combination of LPS+IC, then cell lysates were taken at given time 
points. MSK1 or MSK2 was immunoprecipitated and combined with the substrate, 
recombinant histone H3, in the presence of ATP. Western blots were performed using 
phospho-histone H3 (serine 10) specific antibodies in order to determine if MSK1 or 
MSK2 was activated. These immunoprecipitated kinases were able to phosphorylate 
histone H3. Additionally, immune complexes seem to modulate the activity of MSKs. 
MSK1 has a high level of basal activity that seems to be increased with the addition of 
immune complexes with or without the presence of LPS. As to be expected, the activity 
seems to be more robust in the presence of LPS as it is also an activator of the MAPKs. 
MSK2 does not seem to have any detectable basal level of activity. However, in the 
presence of immune complexes MSK2 is activated. Importantly, this seems to have  












Figure 37: Kinase assay for MSK activity measuring phosphorylation of histone H3.  
Macrophages were stimulated with immune complexes (IC) with or without LPS or not 
stimulated (NS) then lysed in the presence of protease and phosphatase inhibitors at the 
given times. Total MSK1 or MSK2 was immunoprecipitated from cell lysates then 
incubated with ATP and recombinant human histone H3 for 15’ at 30°C. Samples were 
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kinetics similar to the pattern of phosphorylation at the IL-10 locus in that there is an 
increase in activity to at least 30 minutes, but at 60 minutes this activity appears to be 
tapering off. As expected, the presence of LPS increases the induced MSK2 activity 
(Figure 37). 
 
Use of the Inhibitor H89 and MSK1/2 siRNA Blocks IL-10 Production 
In order to first assess the potential role of the MSKs in the super-induction of IL-
10, we first used the inhibitor H89. This inhibitor has previously been shown to primarily 
inhibit the activity of certain isoforms of PKA and PKC
181
. However, this inhibitor has 
also been shown to have a potent inhibitory effect against the MSKs, but not the MAPKs 
or RSKs
114
. Although this inhibitor is helpful for potentially ruling out the MSKs in IL-
10 production, it can not be used to definitively implicate the MSKs in the production of 
IL-10. Macrophages pre-treated with H89 decreased IL-10 production in a dose 
dependant manner, with IL-10 levels after stimulation with LPS/IC nearing that of LPS 
alone (Figure 38A). IL-12/23p40 production was increased by the presence of H89 
(Figure 38B). 
In order to more directly address whether the MSKs played a role, an siRNA 
(small interfering RNA) approach was employed. Although either MSK1 or MSK2 may 
be involved in the chromatin remodeling at the IL-10 locus via phosphorylation of 
histone H3, the possibility exists that MSK1 and MSK2 are redundant or interchangeable 
kinases in the regulation of IL-10. If the expression of either MSK1 or MSK2 is knocked 
down by siRNA transfection, IL-10 production may still be induced despite the lack of 
one kinase. To this address this possibility, an siRNA target was based within the highly  
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Figure 38: Cytokine production in the presence of the inhibitor H89.  
Macrophages were pretreated with increasing concentrations of the inhibitor H89 (5-
20µM) or vehicle control (0.2% DMSO) for 1h, then stimulated with LPS (10ng/ml) or 
LPS/IC overnight. Supernatants were collected and assayed for IL-10 (A) or IL-12/23p40 
(B) concentrations as measured by ELISA.  
















Figure 39:  siRNA design for MSK2 and MSK1/2. 
(A) MSK2 cDNA sequence 1621-1680. Bold and italicized denotes the target of the 
siRNA against MSK2. (B) Alignments made between MSK1 (2079-2208) and MSK2 
(1752-1881) cDNA in a region of significant homology. Bold and underlined denotes 
nucleotides that differ from MSK2 to MSK1. Bold and italicized denotes the target for 
the siRNA against MSK1 and MSK2. The 21 base target is based on the MSK1 template, 











2079 agaccccgtgcttcaccctccactacgcagcaccggagctcttgacgcacaatggctacg 2138                                    
1752 agacTccTtgcttcacActGcaGtacgcTgcacccgagctGCtgGcAcaGCaGggctacg 1811 
2139 atgagtcctgtgacctgtggagcttgggtgtcatcctgtatacaatgctgtcagggcagg 2198 
1812 atgagtcctgCgaTctAtggagcCtgggtgtcatTctgtaCaTGatgctgtcTggCcagg 1871 
2199 tgccattcca 2208 
1872 tTccCttcca 1881                           Identities: 104/130 (80%)  
A. 
1621 ggcaggcgtggtgcaccgcgacctgaaacccgagaacatcttgtacgcggacgacactcc 1680 
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conserved region in the cDNA sequences of MSK1 (2079-2208) and MSK2 (1752-1881) 
(Figure 39B). The 21 base target was based on the MSK1 template, however 18 bases are 
conserved in MSK2 with 17 bases conserved consecutively. Additionally, another siRNA 
target was found for MSK2 (Figure 39A) which does not have any significant homology 
to MSK1. Macrophages were transfected with each of these siRNAs as well as a negative 
control scramble siRNA for 48 hours then assayed for cytokine production upon 
stimulation with LPS with or without immune complexes overnight. Concentrations of 
IL-10 and IL-12/23p40 were determined by ELISA. Macrophages transfected with only 
MSK2 siRNA did not seem to have modified cytokine production from the negative 
control (scramble), however those transfected with MSK1/2 siRNA had severely limited 
IL-10 production (Figure 40A). Silencing of MSK2 transcript with MSK2 siRNA and 
MSK1 and MSK2 transcript with MSK1/2 siRNA was confirmed with real time PCR. As 
mentioned above, both MSK1 and MSK2 could potentially be interchangeable in their 
role in IL-10 production. Knocking out just one kinase with siRNA against MSK2 may 
not be enough to effect IL-10 production significantly, so knocking out both MSK1 and 
MSK2 may only be enough to effect IL-10 production. 
 
MSK1/2 Double Knockout Macrophages Retain Their Ability to Produce IL-10 
 As there is the possibility of off-target silencing when using siRNA, we obtained 
macrophages from MSK1/2 double knockout mice
182
. Macrophages stimulated with 
LPS+IC retained their ability to produce high levels of IL-10 in both wild type and  
MSK1/2
-/-
 cells (Figure 41A), without any significant difference between the them. These 
knockout cells, however, did have enhanced IL-12 production from LPS and LPS+IC 
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Figure 40: Cytokine production after transfection with siRNA for MSK1/2. 
BMMΦ were transfected with siRNA for MSK2, MSK1/2, or a control scrambled 
double-stranded RNA for 48 hours, then stimulated with LPS (10ng/ml) or LPS+IC 
overnight. Cell culture supernatants were then tested by ELISA for IL-10 (A) or IL-
12/23p40 (B).  
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Figure 41: Cytokine production from MSK1/2 double knockout cells (MSK1/2-/-). 
Wild type and MSK1/2
-/-
 BMMΦ were stimulated with LPS or LPS+IC for 4, 8, or 16 
hours before supernatants were collected. Supernatants were assayed for IL-10 (A) or IL-
12/23p40 (B) concentrations by ELISA. Experiments are representative of 2 two 
independent experiments.  
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 stimulated macrophages (Figure 41B). Therefore, based on the knockout data, we 
conclude that the MSKs do not seem to play any direct role in superinduction of IL-10 
due to LPS+IC stimulation. 
 
The Role of Phosphoinositide 3-kinase in the Regulation of IL-10 
 Previous work in the lab has shown the requirement for Fcγ-receptor mediated 
Syk activation in the regulation of IL-10 by MΦ-II though the activation of ERK
117
. 
Crosslinking of the FcγR by immune complexes initiates the activation of Syk, which in 
turn leads to the activation of Ras and PI3K (Figure 2)
16
. Both of these pathways are able 
to mediate the activation of the MAPK by FcγR crosslinking. Previous unpublished 
observations showed no role for Ras activity in regulating IL-10, leading to the 
possibility that PI3K may instead play a role in regulating MAPK activity and thus IL-10. 
In order to address this, macrophages were pretreated with increasing concentrations of 
the PI3K inhibitor LY294002 (1-20µM), then stimulated with LPS or LPS+IC. LPS+IC 
mediated IL-10 production was severely attenuated by the presence of the LY294002 in a 
dose dependant fashion (Figure 42A). Additionally, LPS mediated IL-12/23p40 was 
moderately enhanced by the presence of the inhibitor (Figure 42B). Therefore, PI3K does 
appear to play a role in the regulation of IL-10. The role of PI3K in the reciprocal 
regulation of these two cytokines will be the subject of future investigations in the lab.   
 
Discussion 
 Previous work in the lab has shown that ERK-mediated phosphorylation of 
histone H3 leads to enhanced accessibility to the IL-10 promoter and thus enhanced IL- 
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Figure 42: Production of IL-10 by MΦ-II is severely attenuated by the presence of 
the phosphoinositide 3-kinase inhibitor LY294002. 
Macrophages were pretreated for 1 hour with increasing concentrations of PI3K inhibitor 
LY294002 or vehicle control, then stimulated with LPS or LPS+IC overnight. 
Supernatants were assayed for IL-10 (A) and IL-12 (B) concentrations by ELISA. 
Figures are representative of at least three independent experiments.  
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10 production
106
. Histone H3, however, is not phosphorylated directly by ERK, but is 
instead phosphorylated by a MAPK associated protein kinase (MK). Potential MKs that 
have been proposed to modify histones include RSK2, MSK1, and MSK2. As discussed 
above, there is some controversy as to the actual histone kinase, as studies using RSK-2 
knockouts did not appear to be reproducible
115
. Therefore, we focused on MSK-1 and 
MSK2. The kinase activity of these proteins is enhanced by the presence of immune 
complexes. MSK1 appears to have a great deal of constitutive activity that is moderately 
enhanced by the presence of immune complexes, while MSK2 does not appear to have 
any constitutive activity but is enhanced by the presence of immune complexes. Both the 
inhibitor H89, as well as the MSK1/2 siRNA severely attenuated the production of IL-10 
after stimulation with LPS+IC. These studies suggested that MSK1 or 2 may play a role 
in the regulation of IL-10. Most importantly, however, the lack of MSK1/2 activity in 
knockout cells did not significantly affect IL-10 production after stimulation with 
LPS+IC. Therefore, we concluded that neither MSK1 nor MSK2 appears to play a role in 
the regulation of IL-10. They do, however, appear to play a role in regulating excessive 
IL-12/23p40 production in response to LPS.  
Recently, it was recognized that the HIV Tat (Transactivator of transcription) 
protein interacts with RSK2 and activates RSK2 kinase activity and is responsible for 
hyperphosphorylation of histone H3 within the integrated HIV promoter
183
. It is of note 
that Tat activity has been shown by several groups to be associated with the production of 
IL-10 by monocytes and macrophages
184
. Therefore, it may be possible that Tat activates 
RSK2 which may in turn hyperphosphorylates the promoter of the host gene IL-10, 
allowing for IL-10 production. Therefore, further work on the role of the histone kinases 
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in the regulation of IL-10 should focus on the role of RSK2. The RSK inhibitors BI-
D1870 and SL0101, which have been used to establish RSK2 in regulating dendritic cell 
phagocytosis
185
, should first be used to establish whether RSK plays a role in IL-10 
production and histone phosphorylation. If this is the case, addressing whether conditions 
which enhance the activity of RSK2, possibly though expression of the Tat protein or by 
transfection, may represent a novel way to modulate IL-10 production by macrophages.     
Additionally, the lab had previously shown a role for Syk in regulating ERK 
activity after engagement of the Fcγ receptors by the presence of IgG-immune 
complexes
117
. Syk mediates its activity through the activation of SOS which in turn 
activates Ras or through the activation of PI3K. Our unpublished results have shown that 
Ras activity is not required in the regulation of IL-10, therefore the activation of PI3K 
may be required for the activation of ERK via Syk. In the presence of LY294002, a 
specific inhibitor of PI3K, we show that the production of IL-10 after stimulation of 
macrophages with LPS+IC is severely attenuated, leading us to believe that PI3K is 
required. Future research should focus on the role of PI3K, possibly by assessing ERK 
after stimulation with immune complexes in the presence of LY294002 or the traditional 
inhibitor wortmannin.   
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